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Abstract 
 
Hepatic gluconeogenesis is important for maintaining steady blood 
glucose levels during starvation and through light/dark cycles.  The regulatory 
network that transduces hormonal and circadian signals serves to integrate these 
physiological cues and to adjust glucose synthesis and secretion by the liver.  
However, questions remain as to what factors are involved in coordinating 
circadian signalling and metabolic regulation.  We identified ubiquitin-specific 
protease 2 (USP2) as an inducible regulator of hepatic gluconeogenesis that 
responds to nutritional status and clock signalling.  Adenoviral-mediated over-
expression of USP2 in the liver promotes hepatic glucose production, whereas 
RNAi knockdown of this factor results in hypoglycemia due to impaired hepatic 
gluconeogenesis.  USP2 is required for maintaining diurnal glucose homeostasis 
during restricted feeding.  Elevated hepatic gluconeogenesis exacerbates the 
development of hyperglycemia in diabetes.  In vivo gain- and loss-of-function 
studies demonstrated that USP2 regulates systemic glucose metabolism in 
insulin resistant states through modulation of hepatic glucocorticoid signalling 
and the gluconeogenic program.  Interestingly, we found that USP2-45 is 
localized to the peroxisome in culture primary hepatocytes; however, what role 
this plays in USP2 function remains unclear.   
! xviii!
USP2 mRNA levels are regulated by both fasting and circadian signals.  
To identify key factors involved in USP2’s regulation I employed a gene reporter 
assay.  From these experiments I identified the PPAR gamma co-activator 1 
(PGC-1) family of transcription factors as positive regulators of USP2 expression.  
This activation was mediated in part by circadian regulated transcription factors: 
estrogen-related receptor gamma (ERRγ) and hepatic nuclear factor 4-alpha 
(HNF-4α)  and antagonized by E4 binding protein 4 (E4BP4, Nfil3).  Together, 
my work delineates a novel pathway that links hormonal and clock signalling to 
hepatic gluconeogenesis and glucose homeostasis. 
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Chapter 1 
 
Introduction 
 
1.1. Emerging Health Risks Associated with Increases in Obesity 
An increased sedentary life-style as well as excessive consumption of 
energy-rich foods has led to the increase in the prevalence of obesity worldwide.  
Obesity is a growing epidemic in the industrialized world as well as developing 
countries.  It is estimated that 1.1 billion people are diagnosed as over-weight 
with a body-mass index (BMI) over 25kg/m2, of which 300 million are considered 
obese (BMI = 30 kg/m2 or greater).  Additionally, it is estimated that 155 million 
children are over-weight or obese worldwide [1, 2].  Also increased BMI is 
associated with decreased life expectancy.  Studies done in the UK estimate that 
a BMI of 25 kg/m2 decreases the life expectancy of adult men by two years and 
projects up to a five year decrease in life expectancy by 2050 [1, 3].  In the 
United States approximately 280,000 deaths annually are 
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attributed to obesity and the direct and indirect costs of obesity were estimated at 
$123 billion for 2001 [2, 4].  Thus, obesity is not only a burden to the individual 
but it is also damaging to society as a whole.  It is therefore necessary to 
elucidate not only the epidemiological factors involved in obesity but also the 
molecular factors that underlie the physiological state.  Herein we will look at the 
morbities of obesity specifically focusing on insulin resistance and regulation of 
glucose homeostasis.  
 
1.1.1.  Metabolic Syndrome and Type 2 Diabetes (T2DM) 
Obesity, in this case centralized obesity, is just one aspect of a cohort of 
conditions termed ‘metabolic syndrome’ (MetS) which includes:  excessive 
adiposity, insulin resistance, dyslipidemia and increased blood pressure [5].  
Furthermore, this cluster of conditions leads to an increased risk of 
cardiovascular disease (CVD) as well as a 5-fold increase in developing type 2 
diabetes mellitus (T2DM) [6].   
In humans, T2DM is a polygenic, heterogeneous disease that results in 
the loss of insulin sensitivity (insulin resistance) in peripheral tissue (liver, muscle, 
and adipose tissue), characterized by hyperglycemia, hyperinsulinemia and 
hypertriglyceridemia. Insulin resistance in T2DM occurs post-receptor, referring 
to a dysfunction in down-stream insulin signaling rather than dysfunction in 
release of the hormone.  While the exact diagnostic parameters vary amongst 
different organizations, a core set of criteria are needed for diagnosis of T2DM.  
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During post-prandial food absorption insulin stimulates glucose uptake in muscle 
and fat tissue via the glucose transporter, GLUT4.  Insulin also suppresses 
glucose production in the liver (termed hepatic glucose production or HGP) and 
increases glucose storage in the form of glycogen. In the initial stages of T2DM, 
decreased insulin sensitivity in peripheral tissues, primarily in muscle and fat, 
results in excessive amounts of circulating glucose.  To compensate the β-cells 
of the pancreas increase production and release of insulin to aid in disposal of 
the excess glucose.  As the disease progresses insulin is less able to repress 
hepatic glucose production resulting in further increases in circulating glucose.  
Finally, β-cells start to fail, resulting in diminished insulin secretion and a 
breakdown in glucose homeostasis [7, 8].   
 
1.1.2.  Role of Liver in maintaining Glucose Homeostasis 
As stated above, one aspect of hyperglycemia in T2DM is an increase in 
glucose production from the liver.  Glucose is an important energy source for 
many cells throughout that body and therefore must be maintained within a 
critical range.  Several pathways control the flux of glucose including the rate of 
consumption and absorption of carbohydrates, as well as the disposal and 
utilization of glucose in peripheral tissues (ie muscle and fat).  Glucose 
homeostasis is also highly regulated by the liver.  The liver in general has a 
tremendous affect on glucose homeostasis involving balances between glucose 
storage (glycogen) and breakdown (glycogenolysis & glycolysis) as well as de 
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novo glucose production termed gluconeogenesis.  In must be pointed out that 
gluconeogenesis also occurs in kidney tissue.  However, it is still being debated 
as to how much this renal glucose output contributes to overall glucose 
production - in humans the estimate ranges from 5-23%.    During times of 
starvation, glycogen breakdown (glycogenolysis) in the liver aids initially in 
maintaining blood glucose levels, which are regulated inpart by increased 
circulation of the hormone glucagon – released from the α-cells of the pancreas.  
However, as glycogen stores become depleted, the liver increases the rate of 
gluconeogenesis using lactate, glycerol and gluconeogenic amino acids as 
precursor substrates.  
Hepatic glucose production is a tightly regulated process including 
hormonal input (insulin and glucagon as well as others) and the transcriptional 
and non-transcriptional regulation of several rate-limiting enzymes including 
Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose-6-phosphatase 
(G6Pase).  PEPCK is the first rate-limiting step in gluconeogenesis and catalyzes 
oxaloacetate to phosphoenolpyruvate (PEP).  While G6Pase catalyzes the final 
step producing free glucose from glucose-6-phosphate (G6P) [9].  Since glucose 
is passively transported into the bloodstream via GLUT2, G6pase can be thought 
of as the gatekeeper of glucose production in the liver. Disruption of PEPCK or 
G6Pase has a dramatic affect on glucose homeostasis.  Mutations in the G6Pase 
gene lead to glycogen storage disorder 1a (GSD1a) characterized by 
hypoglycemia and increase liver glycogen content [10].  G6pase null mice also 
display characteristics of GSD1a including hypoglycemia [11].  Additionally, liver 
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specific knock-out of PEPCK leads to marked impairment of hepatic 
gluconeogenesis while total body knock-out causes severe hypoglycemia and 
resulting death [12, 13] .  While there is some evidence that PEPCK might be 
allosterically regulated, it is generally accepted that alterations in PEPCK and 
G6Pase mRNA levels control the overall activity of the enzymes and therefore 
gluconeogenesis.  This tight transcriptional regulation can be observed best by 
the multitude of transcription factors found to bind to proximal promoters of both 
genes [14, 15].  
 
1.1.3.  Glucocorticoid Signaling In Liver Tissue  
Glucocorticoids (GCs) are a class of steroid hormones that regulate 
numerous physiological pathways including:  glucose homeostasis, protein and 
lipid metabolism as well as a therapeutic role in anti-inflammation.  Here we will 
focus primarily on GCs role in liver physiology.  Indeed GCs have an important 
role in regulating gluconeogenic genes, PEPCK and G6Pase (Section 1.1.2), and 
therefore have been shown to oppose the action of insulin and decrease glucose 
utilization.  To this end GCs have been categorized as catabolic hormones.  The 
synthesis of glucocorticoids originates in the cortex of the adrenal gland, which is 
under the control of the hypothalamus-pituitary-adrenal (HPA) axis.  In humans, 
glucocorticoids circulate as a protein-bound inactive precursor (cortisone) that 
can be converted into active hormone (cortisol) in tissues by 11β-hydroxysteroid 
dehydrogenase 1 (HSD11β1 or HSD1), an endoplasmic reticulum (ER) 
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membrane protein [16, 17]. Indeed the term glucocorticoid derives from the 
words; glucose, cortex and steroid [18].   
The principle action of GCs is through its activation of the glucocorticoid 
receptor alpha (GRα, henceforth referred to as GR), a nuclear receptor that 
resides in the cytoplasm (or resides predominantly in the cytoplasm [19]) when 
unbound.  Like many others in the nuclear receptor class, GR contains a co-
activation domain in the N-terminal (NTD) which is required for interactions with 
other co-factors, a DNA binding domain (DBD) responsible for binding to its 
response element and a ligand binding domain (LBD) which is important for 
ligand activation as well as interactions with various co-factors.  In the unbound 
state, GR is complexed with heat-shock proteins: hsp40, hsp70, and hsp90, as 
well as p23 and p60 [20].  Upon ligand binding GR dissociates from the inactive 
complex and translocates to the nucleus whereupon it binds, as a dimer, to its 
target response element, GRE (glucocorticoid response element; 
GGTACAnnnTGTTCT).  Once bound to its response element GR recruits and 
interacts with co-activators such as CBP, SRC-1, p300/CBP and GRIP-1 
increasing histone acetylation, opening up the chromatin and allowing for the 
recruitment of the RNA polymerase II, complex increasing gene transcription [21].  
While glucocorticoid action can be thought of as a primary response on gene 
transcription, there can also be secondary responses to GC signalling via up-
regulation of certain transcription factors or co-activators that propagate the GC 
signal.  Furthermore, many genes not only require GR and a GRE for activation, 
but also rely on other transcription factors and binding sites for proper regulation.  
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This clustering of binding sites is referred to as a glucocorticoid responsive unit 
(GRU).  This has been shown to be true for genes involved in hepatic 
gluconeogenesis, like PEPCK, which contains not only GR binding sites but also 
binding sites for liver enriched transcription factors HNF-4α, FoxA2, and 
C/EBPα [21].   
Excess activity of glucocorticoid signalling has been implicated in the 
development of glucose intolerance in patients with Cushing’s Syndrome and 
also contributes to the pathogenesis of metabolic syndrome [22-25]. Tissue-
specific activation of glucocorticoid signalling by transgenic expression of HSD1 
leads to the development of key features of metabolic syndrome, including 
central obesity, glucose intolerance, and hypertension [26, 27]. On the contrary, 
HSD1 inhibitors, such as carbenoxolone (CBX), improve glycemic control in 
rodents as well as in humans, in part through attenuation of hepatic 
gluconeogenesis and glucose output [24, 28-31].  In fact, identifying new 
inhibitors for HSD1 is a hotbed of research in the type 2 diabetes field.     
 
1.2.  Circadian Rhythm  
Circadian rhythms (Latin:  Circa-,  ‘approximately’ and -diem, ‘day’) are 
recurring biological processes such as:  eating, sleeping, loco-motor activity and 
wakefulness that run roughly on a 24hr cycle.  These physiological behaviors are 
coordinated by an intricate set of internal, endogenous, molecular “clocks” that 
maintain synchrony with environmental cues (e.g. light-dark cycles).  Internal 
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molecular clocks (also known as circadian clocks) have been described in almost 
all forms of life on earth from prokaryotes to higher order eukaryotes such as 
mammals [32, 33].  This phenomenon has also been observed in primary 
cultures and immortalized cell lines like NIH3T3 cells [34-37].  Two important 
characteristics of these circadian clocks are 1.) the free-running period of 24hrs 
is temperature compensated, which is to say the clock does not run faster or 
slower with respect to the ambient temperature and 2.) biological clocks can be 
entrained (i.e. synchronized) to environmental stimuli such as light, 
feeding/fasting and temperature such that internal, or endogenous, time 
becomes predictive of external time [38, 39].  It is thought that these circadian 
rhythms evolved as a selective advantage for organisms to coordinate cellular 
energy metabolism with the environment, and temporally segregate mutually 
antagonistic systems (e.g. glycolysis/ gluconeogenesis) [38, 40-42].  Furthermore, 
mounting evidence suggests not only does circadian clock directly regulate 
metabolic processes, but also that metabolic parameters affect the actions and 
functions of circadian clocks [41, 43-47].  Because of this, circadian clocks and 
metabolic processes are thought to be intricately connected and not as simple as 
a linear relationship [42, 48].     
 
1.2.1.  Circadian Rhythm in Mammalian Systems 
In mammals there is a hierarchical organization to circadian rhythm and 
coordination of physiological behaviors.  There is a core molecular clock, or 
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master pace-maker, that is located in the superchiasmatic nucleus (SCN) of the 
hypothalamus [33].  This patch of roughly 10,000 cells is located above the optic 
nerve crossing that can be entrained by light cues relayed from melanopsin-
containing retinal ganglion cells (retino-hypothalamic tract) [42, 49].  Thus this 
light entrain-able central clock is able to disseminate information to peripheral 
tissues to coordinate daily activities such as feeding (although there is evidence 
that a food entrain-able oscillator resides in the dorsomedial hypothalamic 
nucleus, DMH [50, 51]), wakefulness and loco-motor activity (Figure 1-1).  
Experiments in rodents, either through ablation or mutations studies, show the 
SCN to be the master pacemaker coordinating daily activities [33, 52-54].  It is 
also important to note that while ablation of this cluster of cells resulted in a loss 
of behavioral rhythms, it also resulted in loss of corticosterone (cortisone in 
humans) secretion from the adrenal gland.  This suggests that not only does the 
SCN control locomotor activity but it also could play a role in proper maintenance 
of hormonal signaling [51].   
Through molecular analysis it has been revealed that circadian clocks 
exist in most tissues and cell types within vertebrates – these are termed 
peripheral clocks.  These peripheral clocks are not only entrained by cues from 
the central clock but are also highly entrain-able by nutrients [39, 55-57].  It is 
estimated that roughly 5-20% of genes in peripheral tissues display diurnal 
regulation at the transcriptional level and most of these genes are tissue specific 
[43, 46, 48, 58, 59].  Tissues such as the liver have inputs from the central clock 
regulating glucose homeostasis, but the liver has also been shown to contain a 
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robust molecular clock of its own.  Many of the genes that oscillate in the liver 
involve metabolic pathways such as:  glycolysis and gluconegenesis, cholesterol 
and lipid homeostasis as well as xenobiotic metabolism. [41, 43, 45, 60].   
 
1.2.2.  Molecular Machinery Controlling Circadian Rhythm 
The molecular underpinnings of the intracellular circadian clock reside in a 
series of interlocking transcription/translation feedback loops that results in a 
gene expression profile with a roughly 24h periodicity.  It should be noted 
however, that it has recently been described that in some cell types a nucleus is 
not required for a properly functioning clock. The activating arm of this feedback 
loop is composed of a heterodimeric transcription factor complex, containing 
Circadian Locomotor Output Cycles Kaput (CLOCK) and Brain and Muscle Arnt-
Like protein 1 (BMAL1), which are members of the basic helix-loop-helix PER-
ARNT-SIM (bHLH-PAS) protein family.  This heterodimeric complex regulates 
Period (Per) and Cryptochrome (Cry) genes - via an E-box (5’ -CACGTG- 3’) 
element in the promoters of both genes.  The products of these genes form 
dimers and translocate back to the nucleus to inhibit BMAL1:CLOCK 
transcriptional activity.  Accumulation of the PER:CRY complex causes ubiquitin 
mediated proteasomal degradation of the  PER:CRY complex, resulting in de-
repression resetting the feedback loop allowing it to start again (Figure 1-2).  The 
timing of the proteasomal degradation of PER and CRY is in part carried out by 
the casein family of kinases CK1δ and CK1ε.  The layered nature of this   
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Figure 1-1.  Integration of the central pacemaker of the SCN and peripheral 
clocks involved in metabolic regulation.  Light signals derived from the retina 
are relayed via the RHT to the SCN.  The SCN is then able to synchronize and 
entrain peripheral clocks by either modulating circulating hormones or by 
autonomic innervation.  Also, feeding cycles are able to entrain the SCN but also 
plays a direct role in synchronizing peripheral clocks like that of adipose, liver 
and muscle tissue. 
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feedback loop allows for multiple points of input to fine-tune the running of the 
core clock.  A second, well characterized feedback loop involves the binding 
competition of Retinoic acid receptor-related Orphan Receptor alpha (RORα), 
and REVerse ERythroBlastosis virus alpha (REV-ERBα) for the RORE in the 
Bmal1 promoter.  RORα through interactions with Peroxisome Proliferator-
Activated Receptor {gamma] Coactivator 1-alpha (PGC-1α), activate transcription 
of BMAL1 where as REV-ERBα represses transcription [61].  This alternating 
occupancy of the RORE is made possible by the rhythmic expression of REV-
ERBα – driven by the BMAL1:CLOCK complex [40, 42, 51, 62]  
 
1.2.3.  Linking Circadian Rhythm and Metabolic Disorders 
Mounting evidence suggests that perturbations in feeding habits cause a 
dramatic effect on clock signaling and clock-controlled output behaviors.  Recent 
studies show that diets rich in fat have a profound effect on rhythmic behaviors 
such as locomotor activity and feeding habits.  These high-fat diets also lead to a 
disruption in a properly functioning clock within metabolic tissues such as liver 
and adipose [40, 47].  It was also observed that high-fat diets cause a marked 
disruption in circulating hormone levels such as leptin, corticosterone and TSH in  
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Figure 1-2. Core molecular clock components.  BMAL1 and CLOCK regulate 
the transcription of the PER and CRY family of genes, which in turn inhibits 
BMAL1 and CLOCK transcriptional activity.  Through interactions with RORα, 
PGC-1α regulates expression of BMAL1 in a rhythmic manner.  This activation is 
inhibited by the nuclear receptor, REV-ERBα (which is induced by BMAL1 and 
CLOCK), through direct competition with RORα for occupancy on the RORE in 
the BMAL1 proximal promoter.    
 
 
 
 
E-box 
Per1-3 
Clock Bmal1  
E-box 
Cry1-2 
Clock Bmal1  
RORE 
ROR 
PGC-1α"
Bmal1 
E-box 
Rev-erbα"
Clock Bmal1  
REV-ERBα"
PERs CRYs 
~ 
~ 
~ 
~ 
Nucleus 
Cytoplasm 
! 14!
humans and rats [40, 63, 64].  Also, evidence points to a loss of circadian control 
of glucose utilization and insulin action in patients with T2DM, further 
strengthening the link between metabolic disorders and circadian rhythm [65, 66].  
Aside from clinical data linking circadian rhythm and metabolic disease 
mounting genetic evidence suggests a link as well.  This can best be 
demonstrated by the metabolic phenotypes that develop in clock mutant and 
knockout mice.  ClockΔ19 mice (C57BL6), that carry a truncated exon 18 as well 
as a full deletion of exon 19, become hyperphagic (increased food consumption) 
and obese displaying symptoms of metabolic syndrome including hyperlipidemia, 
hepatic steatosis and hyperglycemia [67].  In addition, BMAL1 -/- total knockout 
mice displayed dysfunction in glucose tolerance, insulin sensitivity as well as an 
increase in total fat mass.  Liver specific knock-out of BMAL1 displays a 
hypoglycemic state during times of fasting suggesting that dysregulation of 
BMAL1 disrupts glucogeogenesis.  This is further supported by the usual 
circadian rhythmicity of genes involved in gluconeogenesis such as: glucose-6-
phosphate translocase (G6PT1), PEPCK, and glucokinase (GCK), being 
disrupted in BMAL1 -/- knock-out livers [45].  Similar effects are observed when 
sleeping patterns are affected.  Evidence so far collected links short sleep 
durations with increased BMI as well as a higher incidence in T2DM  [68].  
 
1.2.4. PGC-1 Family of Transcriptional Coactivators – Integrating Circadian 
and Metabolic Inputs 
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The PGC-1 family is a potent regulator of energy homeostasis and 
circadian signaling, as briefly stated in Section 1.2.3.  Here we describe the 
family of co-activators, and briefly dissect their role in multiple step of energy 
balance and circadian rhythm focusing primarily on liver physiology. 
 PGC-1α was first identified in brown adipose tissue as an interacting 
partner with PPARγ (a nuclear receptor first identified in regulating adipogenesis,) 
[69].  Soon after two other members of the family were identified: peroxisomal 
proliferator-activated receptor  (gamma) coactivator-1 beta (PGC-1β) and PGC-
1-related coactivator (PRC) [70-74].  PGC-1α is robustly expressed in highly 
oxidative tissues such as skeletal muscle, heart, BAT, brain and kidney and to 
this end has been implicated, along with PGC-1β, in mitochondrial biogenesis 
[75].  
During times of fasting both PGC-1α and PGC-1β aid in coordinating the 
hepatic fasting response. These co-activators interact with the nuclear receptor 
PPARα to coordinate fatty-acid oxidation in liver tissue.  RNAi mediated knock-
down of PGC-1α leads to diminished activation of fatty-acid oxidation genes, as 
well as decreased rates of fatty-acid oxidation in cultured hepatocytes [76].  Also, 
PGC-1α but not PGC-1β has been implicated in coordinating the gluconeogenic 
response in fasting liver tissue through interactions with HNF-4α and FOXO1 [76-
79].  Furthermore, PGC-1α itself is induced by administration of dexamethasone 
(a synthetic glucocorticoid agonist) in vivo - supporting PGC-1α’s role in fasting 
liver.  Ectopic overexpression of PGC-1α in primary hepatocyte cultures is 
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sufficient to increase mRNA of gluconeogenic genes like PEPCK and G6Pase.  
Also, PGC-1α null mice show decreased glucose levels in restricted feeding 
experiments along with decreases in gluconeogenic gene expression [62].  
Interestingly, the PGC-1α null mice showed dysregulation of circadian genes 
suggesting that PGC-1α serves as a potent hub for metabolic and circadian 
regulation.   
 
1.3.  Cellular Role of Protein Ubiquitination 
 
Much of the signaling and regulation in the cell revolves around post-
translational modifications of proteins.  These modifications include, but are not 
limited to, phosphorylation, acetylation and ubiquitination.  Ubiquitination is a 
reversible protein modification that can affect protein stability, function and/or 
localization and has been implicated in multiple cellular processes including:  
protein degradation, cell cycle regulation, DNA repair and chromatin remodeling 
[80, 81].   The covalent attachment of ubiquitin is completed in a series of 
reactions that involves an ubiquitin-activating enzyme (E1), an ubiquitin-
conjugating enzyme (E2) and to a target protein via an ubiquitin ligase (E3).  
Thus, the C-terminus of ubiquitin is covalently attached, in an isopeptide linkage, 
to the e-amino group of the substrate’s lysine (Lys) residue [80-82].  Target 
proteins can have one ubiquitin moiety attached, termed mono-ubiquitinaion, or 
can have several attached in a chain like structure, called poly-ubiquitination.  
Poly-ubiquitination is usually a marker for proteasomal degradtion, while mono-
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ubiquitination has more diverse outcomes [81].  In the human genome there are 
an estimated 600 E3 ligases, which ensure proper substrate specificity.  In 
opposition of the action of E3 ligases are a super-family of deubiquitinating 
enzymes, termed DUBs. 
 
1.3.1.  Deubiquitinating enzymes (DUBs) 
Deubiquitinating enzymes (DUBs) are proteases that catalyze the 
cleavage of ubiquitin or ubiquitin-like proteins (UBLs) from:  ubiquitin-conjugated 
proteins, ubiquitin precursors, ubiquitin adducts and ubiquitinated remnants from 
proteasomal mediated degradation.  DUBs have three generalized areas of 
function.  First, they aid in the maturation of the ubiquitin monomer from a 
proprotein state.  Second, after a protein has been targeted for degradations 
DUBs can rescue ubiquitin from targeted proteins contributing to the pool of free 
ubiquitin.  Lastly, DUBs can antagonize the action of E3 ligases by removing 
ubiquitin from a targeted substrate - this is tantamount to the kinase/phosphatase 
regulatory system [80, 83].  As with the role of ubiquitination, deubiquitination has 
been implicated in many cellular pathways including:  kinase activation, 
proteasomal and lysomal protein degradation as well as transcriptional regulation 
and DNA repair.   The importance of DUB’s in disease models has increased in 
the last decade, as mutations in DUBs have been linked to cancer as well as 
neurodegeneration.  
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There are nearly 100 DUBs encoded by the human genome, categorized 
into 5 distinct families.   Four families encode papain-like cysteine proteases:  
UCH, USP/UBP, OUT and MJD, while a fifth family encodes a metalloprotease 
family, JAMM.  Herein, we will focus on only the Ubiquitin Specific Protease 
(USP/UBP) family of deubiquitinases. 
 
1.3.2.  Ubiquitin Specific Protease 2 
Ubiquitin-specific proteases (USP) constitute a major family of 
deubiquitinases that is emerging as versatile regulators of diverse biological 
processes including; cell cycle regulation, transcriptional regulation, and 
mitochondrial dynamics [84-88].  In humans there are predicted to be over 50 
USP family members making this the largest class of DUBs.  USP’s modulate 
cellular signaling through deubiquitinating substrate proteins.   The catalytic 
domain of USPs can be broken down into 3 subdomains, which can be likened to 
the palm, finger and thumb of a hand [80].  The C-terminal of the ubiquitin moiety 
resides in the groove between the thumb and palm subdomains, while the finger 
interacts with the globular portion of ubiquitin.  Many of the over 50 USP’s in the 
human genome remain poorly characterized.  Herein, we will focus on one USP, 
USP2, and try to demonstrate a novel function in liver glucose homeostasis.   
So far, UPS2 has been characterized as an oncogenic protein shown to 
interact with the E3 ligases Murine Double Minute 2 (MDM2) and Murine Double 
Minute X (MDMX),  as well as with Fatty Acid Synthase (FAS).  Furthermore, 
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USP2 has been shown to interact with an epithelial sodium channel, ENaC [89].  
Deubiquitination of these targets leads to increased stabilization and protein 
function.  USP2 has also been shown to oscillate diurnally in liver tissue and 
shows decreased oscillation in clock defective mice [90].  However, what effect 
USP2 has on liver circadian rhythm or gross liver function remains unexplored.   
 
1.4.  Prospectus 
 Over the past decade we have begun to unravel the factors that control 
circadian rhythm.  It has also been well documented the effect disruption of 
circadian rhythm has on metabolic regulation.  Yet, many questions still remain 
about how hormonal and circadian signals integrate to regulate metabolic 
processes.  USP2 has previously been shown to oscillate in liver tissue, yet 
USP2’s role in circadian rhythm and liver function remains poorly understood.   
Based on these finding we propose the following three aims:   
A) Determine the factors involved in USP2 regulation (Chapter 2). 
B) Evaluate USP2’s role in liver tissue using gain and loss of 
function experiments. (Chapter 3). 
C) Using cell culture models evaluated the sub-cellular localization 
of USP2 (Chapter 4). 
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Chapter 2 
 
Circadian and Nutritional Regulation of USP2-45 
 
2.1.  Background  
It is estimated that between 3-20% genes oscillate in a rhythmic manner; 
these are termed circadian output genes and many display tissue specific 
rhythmicity [1].   Additionally, many of these are regulated by nutritional signals 
such as in fed and fasting states. Previous work has demonstrated that ubiquitin-
specific USP2 shows robust circadian rhythm in liver tissue having a periodicity 
of ~24hrs. Furthermore, close examination of the gene structure of USP2 reveals 
that there are two predominant gene products from this locus (Figure 2-1).  One 
gene product is termed USP2-69, which refers to the molecular mass of the 
protein – 69kDa.  There is a second shorter gene product referred to as USP2-45 
- having a molecular mass of 45kDa. The two gene products share the last 13 
exons composing the C-terminal catalytic domain (Figure 2-1).  However, USP2-
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69 contains a different five prime 276aa encoding exon while USP2-45 contains 
a smaller 50aa encoding exon.  While previous work has established that these 
two transcripts are not the result of alternative splicing, but rather two separate 
gene products being driven by two separate promoters, it is not known whether 
they are regulated in a similar manner.  Herein, we aim to dissect the circadian 
architecture that regulates USP2 expression.  
 
2.2 Results 
2.2.1 USP2-45 is regulated by circadian rhythm  
Previous work demonstrated that ubiquitin-specific protease 2 (USP2) 
oscillates in liver tissue with a periodicity of ~24hrs [2, 3].   The first work profiling 
this oscillation used probes common to the catalytic domain of both USP2-69 and 
USP2-45.  We hypothesized that since previous published work suggested that 
both USP2-69 and USP2-45 were not the result of alternative splicing, and under 
the control of two separate promoters, that their expression might also be 
differentially regulated [4]. 
To address this question, we designed two sets of discriminating real-time 
primers (Figure 2-2A) and measured the mRNA levels in livers of mice 
throughout a 24hr period of time.  First, mice (C57BL/6) were entrained to a 12hr-
light/12hr-dark (12:12h LD) cycle with food and water freely available. Next livers 
were harvested from a group of mice (n=3-5) every four hours for 24hrs and the 
mRNA levels of USP2-69 and USP2-45 were analyzed.  We found  that USP2-45   
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Figure 2-1.  Pairwise global alignment of USP2-69 and USP2-45 amino acid 
sequences.  Alignment of USP2-69 and USP2-45 using ClustalW2 software 
(EMBL-EBI, www.ebi.ac.uk) reveals a conserved catalytic domain in the last 
346aa of each protein.   
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had a more robust circadian oscillation than that of the longer form, USP2-69 
(Figure 2-2B, upper left panel).  Also, USP2-45 oscillation is not specific to liver 
tissue as we observe a similar rhythmicity in skeletal muscle (quadriceps) from 
the same cohort of mice (Figure 2-2B, upper right panel).  As a positive control 
for our circadian liver samples we analyzed the expression of two core clock 
genes; BMAL1 and REV-ERBα.  As expected we observed a robust oscillation of 
BMAL1 and REV-ERBα in opposite phase of one another in both liver and 
muscle tissue (Figure 2-2B, lower panels).  These data suggest that USP2-45 
expression is highest around zeitgeber time ZT10-12 (ZT, ZT0 is the onset of 
light phase) and reaches its nadir around ZT 4. 
 We next posed the question whether a properly functioning molecular 
clock was required for USP2-45 rhythmicity in liver tissue.  To address this 
question we employed the use of a BMAL1 liver specific knock-out (LKO) mouse 
line.  Previous work on this liver specific knock-out demonstrated that lack of liver 
BMAL1 resulted in a disruption of proper circadian rhythm compared to wild-type 
controls [5].  We proceeded as describe above; mice were kept on a 12:12 LD 
cycle and mice were sacrificed (n=3-5) every 4 hours for a period of 24hrs.  As 
expected there is no detection of Bmal1 in liver specific knock-out mice (Figure 
2-3, upper left panel) Interestingly though, when BMAL1 is absent we see a 
complete disruption of USP2-45 rhythmicity (Figure 2-3, upper-right panel).  We 
do observe increased expression of USP2-45 in BMAL1 LKO mice at the nadir of 
USP2-45 expression at time points ZT 1 and ZT 22.  Except for ZT 4 all other 
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Figure 2-2.  USP2-45 demonstrates diurnal oscillation in liver and muscle 
tissue.  (A) Diagram of USP2 gene structure and the position of the real-time 
primers used to discriminate between USP2-69 and USP2-45.  (B) Circadian 
oscillation of USP2-69 and USP2-45 in liver and muscle tissue as well as Bmal1 
and Reverbα (n=3-5).  Bmal1, brain and muscle ARNT-like 1; Rev-Erbα.  Data 
represent mean ± s.em.  * p < 0.05. 
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time points are significantly lower compared to BMAL1 wild-type mice.  In 
addition, PEPCK and E4BP4 (Nfil3, a transcriptional repressor) are also 
rhythmically disrupted in BMAL1 LKO mice.  It is interesting to point out that the 
two time points (ZT 1 and ZT 22) where USP2-45 expression is higher in BMAL1 
LKO mice E4BP4 levels are significantly lower.  We will address this observation 
in more depth, later in this chapter.  From these studies we conclude that a 
properly functioning clock is required for proper USP2-45 expression.  Whether 
BMAL1 is a direct regulator of USP2-45 rhythmicity remains unclear. 
At this point it must be noted that we have been unable to detect 
endogenous USP2-45 protein consistently due to a lack of specific antibodies 
that react with mouse USP2-45.  We have tried several commercially available 
antibodies but so far without any success.  We will address this shortcoming in 
the “Future Directions” section of this chapter.     
 
2.2.2.  Tissue Distribution 
We also looked at the tissue distribution of USP2-69 and USP-45 (Figure 2-4).  
We again used our discriminating real-time primer sets and looked at brown 
adipose tissue (BAT), white adipose tissue (WAT), skeletal muscle (quadriceps), 
heart, brain, spleen, kidney and liver.  While we cannot quantify the difference of 
USP2-45 relative to USP2-69 in different tissues, because of potential 
differences in primer efficiencies, we can get an idea of how widely expressed 
! 32!
 
Figure 2-3.  USP2-45 circadian oscillation is disrupted in liver specific 
BMAL1 knock-out livers.  One-day temporal expression profile of selected 
circadian and metabolic genes in liver tissue from Bmal1 WT mice (black circle) 
and Bmal1 liver specific knock-out (LKO) mice (white circle).  Shown is the mean 
and SEM of a pooled set of cDNA (n = 4, for each time point) from each time 
point run in triplicate (some error bars are too small to see on this scale).  BMAL1, 
Brain and muscle ARNT-like1; USP-45, Ubiquitin-specific protease 2-45; PEPCK, 
phosphenolpyruvate carboxykinase 1; E4BP4, E4 promoter binding protein 4.  *  
p < 0.05.  
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Figure 2-4.  Tissue distribution of USP2-69 & USP2-45.  Shown is the qPCR 
profile of USP2-45 (white bars) and USP2-69 (black bars) in brown adipose 
tissue (BAT), white adipose tissue (WAT), muscle (quad), heart, brain, spleen, 
kidney and liver tissues.  cDNA was pooled from 2 individual male (C57BL6J) 
mice and run in a triplicate.   
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each gene product is.  USP2-45 seems to be widely expressed in most tissues 
except splenic tissue.  USP2-69 is also similarly distributed amongst tissues 
analyzed.  USP2-45 seems more highly expressed in skeletal muscle, heart, 
brain and kidney than in liver, BAT and WAT.  On the other hand USP2-69 
shows higher expression in BAT and WAT than in skeletal muscle, heart and 
brain tissue.   The physiological relevance of the differences in tissue distribution 
still remains unclear.   
 
2.2.3.  Nutritional regulation of USP2-45 and USP2-69 
Many genes involved in energy metabolism (e.g. fatty acid oxidation, 
lipogenesis, gluconeogenesis) oscillate in a circadian manner due to the rhythmic 
nature of feeding cycles (e.g. fasting/feeding).  These feeding cycles also cause 
oscillations in hormones like insulin and glucagon as well as stress hormones 
such as cortisone (or corticosterone in mice).  Since the peak of USP2-45 
expression occurs around the light-dark transition corresponding to fasting or 
semi-fasting state we hypothesized that USP2-45 might also be regulated by 
nutritional inputs.  To test our hypothesis we again used our 2 sets of 
discriminating real-time primers to elucidate whether USP2-45 or USP2-69 
responds to nutritional signals. 
We found that USP2-45 mRNA expression is significantly induced in 
response to starvation and reduced following overnight refeeding (Figure 2-5A). 
As shown in Figure 2-5A, mRNA expression of USP2-45 is induced by 
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approximately 3.2-fold in the liver during fasting. In contrast, mRNA levels of 
USP2-69 remain similar under these feeding conditions. The induction of USP2-
45 by starvation appears to be liver-specific, as mRNA levels for both isoforms 
remain largely unchanged in white adipose tissue and skeletal muscle.  Since we 
observed a decrease in USP2-45 mRNA levels during refeeding this may 
suggest a role for insulin in repressing the expression of USP2-45.  To test this 
possibility, we injected mice with streptozotocin (STZ) to destroy β-cell function in 
the pancreas - disrupting insulin signaling.  When we injected mice with STZ we 
observed a dramatic increase in the mRNA level of USP2-45 in liver tissue 
compared to saline control mice.  The mRNA levels of USP2-69 remain 
unchanged.  This suggests insulin plays a repressive role in USP2-45 regulation 
in vivo.    
To determine the nature of the starvation signals that regulate USP2-45 
expression, we treated cultured mouse primary hepatocytes with glucagon, 
hydrocortisone, an endogenous glucocorticoid in rodents, and insulin alone or in 
combination. As expected, the combination of glucagon and hydrocortisone 
strongly induces the expression of PEPCK and IGFBP1, known glucocorticoid 
targets in the liver (Figure 2-6, right, upper and lower panel). USP2-45 
expression is robustly induced by hydrocortisone, which is further augmented in 
the presence of glucagon. In contrast, USP2-69 mRNA levels remain largely 
unaffected by these treatments (Figure 2-6, left, upper and lower panel). Similar 
to PEPCK and IGFBP1, the induction of USP2-45 by hydrocortisone and 
glucagon is strongly suppressed by insulin treatments.  These results indicate  
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Figure 2-5.  Nutritional regulation of USP2 isoforms. (A) Realtime qPCR 
analysis of USP2-45 and USP2-69 mRNA in liver, white adipose tissue (WAT), 
and skeletal muscle from fed (open), fasted (filled), and refed (gray) mice.  
Shown below is a schematic of the USP2 gene locus and the qPCR primers 
(arrowheads) used to detect USP2-45 and USP2-69 isoforms. Data represent 
mean ± s.e.m (n=4). (B) Realtime qPCR analysis of USP2-45 and USP2-69 
mRNA in liver treated with saline (open) or STZ (filled).  Data represent mean ± 
s.e.m (n=3).  * p < 0.05. 
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Figure 2-6.  Hormonal control of USP2 isoforms.  qPCR analysis of total RNA 
from primary hepatocytes treated with hydrocortisone, glucagon and insulin (6hr 
treatment). Data represent mean ± stdev of samples from one representative 
experiment assayed in triplicate. * p < 0.01, hydrocortisone plus glucagon vs. 
control. # p<0.01 insulin vs. no insulin.       
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that USP2-45 is regulated by nutritional signals (e.g. glucagon and insulin) and is 
a target of hepatic glucocorticoid signaling.  
 
2.2.4.  PGC-1 family of co-activators’ role in USP2-45 regulation 
Previous work done on the PGC-1 family of co-activators has suggested a 
role for coordinating circadian and metabolic signaling [6].  PGC-1α has a role in 
regulating core circadian clock genes such as BMAL1 and REV-ERBα as well as 
gluconeogenic genes like PEPCK and G6Pase.  PGC-1α itself is regulated by 
circadian rhythm as well as being induced during times of food deprivation in liver 
tissue controlling gluconegenesis in the liver [7, 8].  We previously identified 
USP2 as a target of PGC-1α using wild-type primary hepatocyte microarrays in 
gain-of-function experiments.  Using our USP2 discriminating primers we 
observed roughly a 35-fold and 30-fold induction of USP2-45 in primary 
hepatocytes transduced with either adenoviral PGC-1α or PGC-1β (another 
PGC-1 family member), respectively (Figure 2-7A).  Over expression of PGC-1α 
or PGC-1β had no significant effect on USP2-69 mRNA levels.  ERRα and SOD2, 
two known targets of PGC-1α and PGC-1β were also significantly elevated.  All 
results were normalized to cells transduced with adenoviral GFP.  Similar results 
were obtained with C2C12 myotubes transduced with either PGC-1α or PGC-1β 
(Figure 2-7B).  The relative induction of USP2-45 in primary hepatocytes is 
higher than that of C2C12 myotubes.  We attribute this to virus infectivity of 
primary hepatocytes compared to C2C12 myotubes and not elevated base-line 
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levels of USP2-45 in C2C12 cells.  We next sought to elucidate whether this 
regulation was physiologically relevant in vivo.  To test this we transduced mouse 
livers with either adenoviral GFP, PGC-1α (Figure 2-7C), or PGC-1β (Figure 2-
7D).  In both cases we observed a significant increase in USP2-45 mRNA levels. 
Interestingly, we observed a significant decrease in USP2-69 levels in both PGC-
1α and PGC-1β transduce livers.  Again, ERRα and SOD2 were also significantly 
induced suggesting viral transduction of the liver worked.  Taken together this 
work suggests that the PGC-1 family of co-activators is sufficient to drive 
induction of USP2-45, specifically.  However, the PGC-1 family does not contain 
a DNA binding domain and therefore must interact with other DNA-binding 
factors to regulate transcription [9].  Because of this we next wanted to identify 
transcription factors that facilitated PGC-1’s regulation of USP2-45.   
 
2.2.5.  Factors involved in USP2-45 regulation 
 To identify factors involved in the regulation of USP2-45, we cloned out a 
3.7kb fragment of the proximal promoter.  We then used this construct to perform 
promoter reporter luciferase based assays in BOSC cells.  For these experiments, 
we will be using luciferase enzyme activity as a marker for promoter activity.  We 
initially narrowed our list of transcription factors to a handful of known PGC-1 
interacting partners (both from published and unpublished (lab data) sources) [9]. 
From this screen we identified hepatic nuclear factor 4-alpha (HNF-4α)  and 
estrogen-related receptor gamma (ERRγ) as potent regulators of the USP2-45 
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Figure 2-7.  Over-expression of PGC-1α or PGC-1β is sufficient to induce 
Usp2-45 Expression.  PGC-1α and PGC-1β are over-expressed in (A) 1o 
hepatocytes and (B) C2C12 myotubes using an adenoviral delivery system.  
Data represent mean ± stdev of samples from one representative experiment 
assayed in triplicate.  Tail-vein injection was used to deliver PGC-1α (C) and 
PGC-1β (D) adenovirus to liver tissue in mice.  For panel C, n = 6 for both GFP 
and PGC-1α.  For panel D, n = 4 for GFP and n = 5 for PGC-1β.  Data represent 
mean ± s.e.m.  Ubiquitin-specific protease 2-69 (USP2-69), Ubiquitin-specific 
protease 2-45 (USP2-45), Estrogen related receptor alpha (ERRα), Superoxide 
dismutase 2 (SOD2).  *  p < 0.05. 
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3.7kb promoter.  In both instances HNF-4α and ERRγ were able to synergize 
with PGC-1α or PGC-1β on the USP2-45 promoter to drive increases in 
luciferase expression (Figure 2-8A&B).  In fact, over-expression of HNF-4α or 
ERRγ alone was sufficient to significantly increase promoter activity.  Other 
factors included in the screen are shown in Figure 2-8C.  We saw a significant 
increase in USP2-45 promoter activity when both thryroid receptors alpha and 
beta (TRα/TRβ) were cotransfected, separately, with PGC-1α.  However, 
SREBP-1c, RORα, FOXA2 and HCFC1 had little effect on promoter activity 
alone or coexpressed with PGC-1α.  Interestingly, over-expression of GR was 
unable to induce USP2-45 promoter activity (Figure 2-8D).  This was a little 
counter-intuitive and we thought that maybe our GR construct was non-functional.  
To verify the functionality of our GR construct we used a synthetic promoter 
containing a glucocorticoid response element, termed TAT-GRE-luc.  In these 
experiments GR was able to induce luciferase expression in both the absence 
and presence of ligand (DEX) (Figure 2-8E).  This may suggest that the GRE 
responsible for regulating USP2-45 expression resides outside of the 3.7kb 
proximal promoter.  
 Through the use of this small-scale promoter reporter screen we were 
able to identify two potent regulators of USP2-45, HNF-4α and ERRγ.  We next 
tried to elucidate what parts of the USP2-45 promoter were critical for this 
regulation.  To this end we cloned two smaller (0.6k and 1.7kb) fragments of the  
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Figure 2-8.  HNF-4α and ERRγ  synergize with PGC-1α and PGC-1β on the 
3.7kb USP2-45 promoter.  Using a luciferase promoter construct containing the 
3.7kb upstream promoter of USP2-45 demonstrates that PGC-1α and PGC-1β 
can synergize with (A) HNF-4α and (B) ERRγ to increase promoter activity.  
HNF-4α, hepatic nuclear factor 4 (alpha); ERRγ, estrogen related receptor 
(gamma).  (C) Small-scale screen of other known PGC-1α interaction partners; 
TRα, thyroid hormone receptor (alpha); TRβ, thyroid hormone receptor (beta); 
SREBP-1c, sterol regulatory element-binding protein-1c; GR, glucocorticoid 
receptor; FOXA2, forkhead box A2; HCFC1, host cell factor C1, RORα, RAR-
related orphan receptor (alpha).  * p < 0.05  (D) Transfection of GR in 
combination with 3.7kb USP2-45 promoter plus or minus dexamethasone 
(100nM, 6hrs). (E) Transfection of GR in combination with TAT-GRE promoter 
with or without 100nM dexamethasone for 6hrs.  * p < 0.05.  # p < 0.05 GR v. GR 
+ DEX.  Data represent mean of two wells ± stdev.   
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USP2-45 promoter  (USP2-45-luc).  In both the 0.6kb and 1.7kb fragments, ERRγ 
was able to synergize with PGC-1α or PGC-1β to increase luciferase expression 
(Figure 2-9A&B).  However, it does appear the synergy is more robust in the 
1.7kb fragment.  A similar conclusion can be made when looking at HNF-4α.  In 
both fragments HNF-4α is able to synergize with PGC-1α or PGC-1β to increase 
luciferase expression.  But again this synergy is more robust in the 1.7kb 
fragment.  Direct comparison between the two fragments is difficult since their 
baseline activity levels are different.  In these experiments we transfected a 
constant amount of plasmid instead of trying to match activity levels.  Another 
approach would be to titrate in the reporters until a similar baseline is reached 
and then analyze transcriptional regulation.  Regardless, in these experiments it 
does seem as though the 0.6kb fragment is sufficient to increase promoter 
activity.  This maybe due to the 0.6kb fragment containing the bare minimum of 
elements required for proper activation, while the 1.7kb fragment contains more 
regulatory elements - further augmenting the induction.  However, we still have to 
identify binding sites for either ERRγ or HNF-4α.  And the requirement of either 
HNF4-α or ERRγ for proper USP2-45 regulation still remains to be elucidated.    
 So far we have identified transcription factors responsible for the positive 
regulation of USP2-45.  We next wanted to explore what transcription factors 
were involved in the negative regulatory arm of USP2-45.  We focused on four 
prominent repressors of circadian rhythm: small heterodimer partner (SHP,  
 
! 44!
 
 
Figure 2-9. The 0.6kb region of the USP2-45 promoter is sufficient for PGC-
1α and PGC-1β regulation via interactions with HNF-4α and ERRγ .  Reporter 
gene assays using (A) 0.6kb and (B) 1.7kb promoters of USP2-45 in the 
presence of ERRγ, PGC-1α and PGC-1β.  Reporter gene assays using (C) 0.6kb 
and (D) 1.7kb promoters of USP2-45 in the presence of HNF-4α, PGC-1α and 
PGC-1β.  Data represents mean of two wells ± stdev.  * p < 0.05.       
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NROB2), REV-ERBα (Nr1d1), REV-ERBβ (Nr1d2) and E4 promoter-binding 
protein 4 (E4BP4, Nfil3).  We co-transfected BOSC cells with PGC-1α and HNF-
4α (plus 3.7kb USP2-45-luc), and a titrating dose of one of the four repressors.  
In this instance E4BP4 was able to antagonize the stimulatory effect of HNF-4α 
and PGC-1α in a dose dependent manner (Figure 2-10A).  Both SHP andREV-
ERBα had little to no effect on the HNF-4α/PGC-1α activation, while REV-ERBβ 
repressed activation at only a higher dose.  Furthermore, E4BP4 was able to 
repress HNF-4α/PGC-1α activation in both the 0.6kb and 1.7kb fragments 
(Figure 2-10B).  In section 2.2.2, we observed elevated levels of USP2-45 at ZT 
4 and 22 in BMAL1 LKO animals compared to wild-type controls.  This seems to 
correspond to a decrease in E4BP4 mRNA levels in LKO samples (Figure 2-2, 
lower right panel).  It has also been demonstrated that E4BP4 plays a significant 
role in the repressive arm of insulin signaling [10].  This is still mostly 
circumstantial evidence, however, taken together with our promoter reporter 
experiments, E4BP4 may play a major role in the circadian and nutritional 
regulation of USP2-45.  
 
2.3.   Conclusions 
1.) The USP2-45 gene product is regulated by both circadian and nutritional             
      inputs. 
2.) Members of the PGC-1 family of transcription factors are sufficient to induce  
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     USP2-45 expression - both in vitro and in vivo.   
3.) USP2-45 regulation is mediated in part by HNF-4α or ERRγ and is  
     antagonized by E4BP4. 
 
2.4.  Discussion 
 Our studies indicate that USP2-45 was the main isoform of USP2 
oscillating in both liver and muscle tissue and that knock-out of BMAL1, in liver 
tissue, caused complete loss of this rhythm.  The precise molecular basis for 
USP2-45 regulation still remains poorly understood.  However, we have  (through 
reporter gene assays) identified the PGC-1 family of co-activators as potent 
activators of USP2-45.  Both PGC-1α and PGC-1β are rhythmically expressed in 
the liver and PGC-1α regulates core clock genes, including BMAL1 and REV-
ERBα [6].  We also demonstrated that this activation is potentially mediated by 
the nuclear receptors, HNF-4α and ERRγ, and that this activation was 
antagonized by the transcriptional repressor, E4BP4.  
Along with circadian inputs, USP2-45 is also regulated by fasting signals 
in the liver.  In cultured hepatocytes, fasting hormones, hydrocortisone and 
glucagon potently activated, while insulin repressed, USP2-45 expression 
(Figure 2-11).  Given that PGC-1α strongly induces USP2-45 expression, it is 
possible that USP2-45 is a component of the hepatic metabolic response 
orchestrated by PGC-1α during fasting and throughout light/dark cycles. In this  
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Figure 2-10.  E4BP4 antagonizes the action of HNF-4α and PGC-1α on the 
promoter of USP2-45.  (A) Reporter gene assays using 3.7kb USP2-45-luc in 
the presence of SHP, REV-ERBa, REVERBa or hE4BP4.  Reporter gene assays 
using (B) 0.6kb or (C) 1.7kb USP2-45-luc in the presence of hE4BP4.  Data 
represents mean of two wells ± stdev.  * p < 0.05; promoter alone v. HNF-
4α/PGC-1α.  # p < 0.05; HNF-4α/PGC-1α v. HNF-4α/PGC-1α + hE4BP4. 
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Figure 2-11.  Both nutritional and circadian inputs regulate USP2-45 
expression. Members of the PGC-1 transcription co-activator family potently 
activate USP2-45 expression while E4BP4 represses USP2-45 expression.  
Fasting hormones, hydrocortisone and glucagon, induce USP2-45 expression 
while insulin reduces this induction.   
 
 
 
Clock 
Nutritional  
Signals 
USP2-45 
? 
PGC-1α/β#
E4BP4 
BMAL1 
Glucagon#
GC’s 
Insulin 
! 49!
regard USP2-45 may be a direct target of GR, which itself is a transcriptional 
partner for PGC-1α.  Alternatively, PGC-1α may regulate USP2-45 gene 
expression indirectly through its modulation of the clock pathway.  However, 
more work is needed to dissect these emerging regulatory pathways.      
 
2.5.  Future Directions 
2.5.1 USP2-45 protein detection 
 As discussed previously, we were unable to detect protein levels for 
USP2-45.  This is important for validation of our observations regarding 
regulation of USP2-45 mRNA levels.  Since we have tried several antibodies 
against USP2-45 with little success a more aggressive approach might be 
required.  One possibility would be to construct a transgenic line of mice 
containing a HA/Flag cassette at the end of the 13th exon of USP2-45 (also 
would be present in USP2-69.  Alternatively, the cassette could be placed at the 
5’ end of exon 1 of USP2-45. This would lend specificity, as it would not be 
present in the USP2-69 isoform.  This would be similar to a transgenic construct 
but the endogenous regulatory elements would be intact.     
 
2.6 Materials and Methods 
Cultured primary hepatocytes. Primary hepatocytes were isolated from female 
C57/Bl6J mice using collagenase type-II (Invitrogen), as previously described 
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[11]. Hepatocytes were maintained in Dulbecco Modified Eagle Medium (DMEM) 
supplemented with 10% bovine growth serum and antibiotics at 37oC and 5% 
CO2. Cells were switched to DMEM supplemented with 0.1% BSA for 16-24 hrs 
before treatments with hydrocortisone (1µM), glucagon (40 nM) or insulin (100 
nM) for 6 hrs. For adenoviral transduction, recombinant adenoviruses were 
generated using AdEasy  adenoviral vector (Stratagene) as previously described 
[12]. Hepatocytes were transduced for 48 hrs at similar moiety of infection before 
RNA isolation and gene expression analysis.   
 
Gene expression analysis. Total hepatocyte RNA was isolated using Trizol 
(Invitrogen), reversed transcribed using MMLV reverse transcriptase, and 
analyzed by quantitative PCR using Sybr Green method. The primers used for 
qPCR analysis  were described in previous studies [6, 12]. 
 
In vivo mouse studies. C57BL/6J mice were kept on a 12:12 light-dark cycle 
with food and water freely available. For fasting/refeeding studies, mice were 
provided food ad lib, fasted for 20 hrs, or refed for 18 hrs following fasting. 
Tissues were harvested at the same time and frozen, using dry ice, and and 
subsequently prepped for gene expression analysis.  Bmal1 flox/flox mice were 
obtained from the Jackson Laboratory. Liver-specific Bmal1 knockout mice were 
generated by breeding the flox/flox mice with Albumin-cre transgenic mice. 
Tissues were harvested every 3 hrs for a period of 24 hrs for gene expression 
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studies.  The University Committee on Use and Care of Animals (UCUCA) at the 
University of Michigan approved all animal procedures performed in this paper.  
 
Luciferase Assay.  BOSC cells were transiently transfected using either 
Lipofectamine/ Plus Reagent (Invitrogen) or polyethylenimine (Polysciences, Inc.) 
with desired plasmids.  USP2-45 promoter constructs were cloned from liver 
genomic DNA and sub-cloned into the pGL-Basic luciferase vector (Promega).  
25-50ng of reporter was used in each well and all transfection reagents 
contained the same amount of plasmid DNA using pCDNA as an empty vector 
control [6].  Cells were transfected in serum free DMEM, supplemented with 
antibiotics over-night in 24-well plate and 1ml of DMEM, supplemented with 10% 
BGS and antibiotics was added the following day.  Cells were harvested 48 hours 
post-transfection and cell lysates were prepared using the BD MoonlightTM 
luciferase assay system (BD Bioscience) and read using a Molecular Devices 
LMax luminometer.   
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Notes 
Portions of this work are included in a paper in preparation entitled:  “Ubiquitin-
specific protease 2 regulates hepatic gluconeogenesis and diurnal glucose 
metabolism through 11β-hydroxysteroid dehydrogenase 1,” Matthew M. Molusky, 
Siming Li, Di Ma, Lei Yu, and Jiandie D. Lin. 
M. M. Molusky and J. D. Lin designed the experiments and prepared the 
manuscripts.  D. Ma was responsible for BMAL1 liver specific knock-out samples 
shown in Figure 2-3. 
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Chapter 3 
 
USP2-45 Regulates Hepatic Glucose Homeostasis 
 
3.1.  Background  
Hepatic gluconeogenesis is important for maintaining blood glucose 
homeostasis in mammals during prolonged fasting. Glucocorticoids and glucagon 
are major physiological hormones that stimulate the expression of gluconeogenic 
enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-
6-phosphatase (G6Pase), whereas insulin suppresses the action of these 
counter regulatory hormones in the liver [1-3].   
Recent studies have demonstrated that circadian clock exerts profound 
influences on energy metabolism and is required for maintaining energy and 
nutrient homeostasis [4-10]. Disruption of pancreatic clock in mice impairs β-cell 
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function and leads to hypoinsulinemia and diabetes [11, 12], whereas ablation of 
liver clock results in hypoglycemia following starvation and at certain time points 
during the day due to impaired hepatic gluconeogenesis [13, 14]. In addition, 
clock protein cryptochrome (CRY) modulates hepatic cAMP signalling and 
gluconeogenesis [15].  As such, hormonal and circadian signals likely converge 
on key regulatory nodes to coordinate hepatic gluconeogenesis and glucose 
secretion. 
Reversible protein ubiquitination and deubiquination modulate the 
biochemical functions of target proteins. The latter is carried out by 
deubiquitinating enzymes, which remove ubiquitin or ubiquitin-like protein from 
their substrates [16, 17]. Ubiquitin-specific proteases (USP) constitute a major 
family of deubiquitinases that is emerging as versatile regulators of diverse 
biological processes, including cell cycle regulation, signalling, transcriptional 
regulation, mitochondrial dynamics [18-22]. Whether USP members are 
nutritionally regulated and participate in the regulation of glucose metabolism 
remain unexplored.  Here in, we describe the first work done characterizing 
ubiquitin specific protease 2 as a factor controlling hepatic glucose out via liver 
specific increases in glucocorticoid signalling.    
   
3.2 Results 
3.2.1 USP2-45 stimulates hepatic gluconeogenesis and glucose output. 
! 56!
De novo glucose synthesis via gluconeogenesis is essential for 
maintaining blood glucose levels during starvation in mammals. To determine 
whether USP2-45 regulates hepatic glucose production, we transduced chow-fed 
mice via tail vein injection of recombinant adenoviruses expressing GFP (control) 
or Flag/HA-tagged USP2-45. Compared to control, adenoviral-mediated 
expression of USP2-45 in the liver results in elevated plasma glucose and insulin 
concentrations (Figure 3-1A). We next performed pyruvate tolerance test (PTT) 
to directly assess hepatic gluconeogenic function in transduced mice. We inject 
intraperitoneally (i.p.) a single bolus of pyruvate, a gluconeogenic substrate, and 
measured blood glucose levels at different time points. Mice transduced with 
USP2-45 adenovirus have significantly higher blood glucose levels following 
pyruvate injection (Figure 3-1B), suggesting that hepatic gluconeogenic activity 
is augmented by USP2-45. Consistently, we found that mRNA expression of 
PEPCK is increased by USP2-45 (Figure 3-1C). The expression of G6Pase 
remains unchanged. 
We next examined whether USP2 is required for maintaining normal blood 
glucose levels during starvation. We generated recombinant adenoviruses that 
express shRNA directed toward USP2 (Figure 3-2A) and transduced C57BL/6J 
mice with control or siUSP2 adenoviruses. Measurements of fasting blood 
glucose indicate that mice with hepatic knockdown of USP2 have significantly 
lower glucose levels (Figure 3-2B). In addition, circulating insulin concentration 
is also reduced in the knockdown group, although the difference only reaches 
borderline statistical significance (p=0.07). Consistently, we found that mice 
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transduced with siUSP2 adenovirus have impaired ability to convert pyruvate into 
glucose during PTT (Figure 3-2C), suggesting that hepatic gluconeogenesis and 
glucose output are impaired by RNAi knockdown of USP2 in the liver. Gene 
expression analysis revealed that PEPCK mRNA expression is lower in mice 
transduced with siUSP2 adenovirus (Figure 3-2D). We conclude from these 
studies that USP2-45 regulates hepatic gluconeogenesis and is required for 
plasma glucose homeostasis. 
 
3.2.2.   Diurnal regulation of glucose homeostasis by USP2 
In mammals, the biological clock regulates diverse behavioral and 
physiological rhythms, notably pathways of nutrient and energy metabolism [4, 
23-25].  To explore the role of USP2-45 in circadian glucose regulation, we 
transduced C57BL/6J mice with control or siUSP2 (construct #1) adenoviruses 
and measured plasma glucose levels under restricted feeding conditions. 
Restricted feeding has been demonstrated to play a dominant role in setting the 
phase of clock and metabolic gene expression in peripheral tissues [5, 26]. We 
observed significantly lower plasma glucose levels at zeigeitber time (ZT, ZT0 is 
the onset of light phase) 6, 12, and 24, but not ZT18, when mice were fed 
exclusively during dark phase (Figure 3-3A). Following a switch to daytime 
feeding, siUSP2 transduced mice have significantly lower glucose levels at ZT24. 
Gene expression analysis at ZT0 and ZT12 reveals that mRNA levels of USP2, 
PEPCK and glucose-6-phosphate transporter (G6PT), but not G6Pase, are 
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 Figure 3-1. USP2-45 promotes hepatic gluconeogenesis. (A) Plasma 
glucose and insulin concentrations in transduced mice measured under fed 
condition. (B) Pyruvate tolerance test in mice transduced with GFP (open 
squares, n=7) or USP2-45 (filled triangles, n=7) adenovirus. (C) qPCR analysis 
of PEPCK and G6Pase gene expression in livers from mice transduced with GFP 
(open) or USP2-45 (filled) adenovirus. Data in A-C represents mean ± s.e.m. * p 
< 0.05, GFP vs. USP2-45.  
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Figure 3-2.  Knock-down of USP2 in chow fed mice results in 
hypoglycaemia and decreased liver glucose production.  (A) BOSC cells 
were co-transfected with Flag-HA tagged USP2-45 and either siUSP2 construct 
#1 or #2.  Cell lysates were blotted for HA (upper row) to detect USP2-45 knock-
down; protein loading was controlled for by blotting for tubulin (lower).  (B) Blood 
glucose and insulin levels in mice transduced with control or siUPS2 adenovirus 
following overnight fast. (C) Pyruvate tolerance test in mice transduced with 
control (filled squares, n=6) or siUSP2 (open triangles, n=7) adenovirus. (D) 
qPCR analysis of liver gene expression from mice transduced with control (filled) 
or siUSP (open) adenovirus. Data in D-F represents mean ± s.e.m. * p < 0.05, 
control vs. siUSP2.  
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Figure 3-3. USP2-45 regulates circadian glucose metabolism.  (A) Blood 
glucose levels in mice transduced with control (red, n=11) or siUSP2 (blue, n=12) 
adenovirus with feeding restricted to night-time (upper panel) or three days after 
a switch to day-time feeding (lower panel).  Data represents double plotted mean 
± s.e.m. (B) qPCR analysis of liver gene expression from restricted day-time fed 
mice transduced with control (filled) or siUSP2 (open) harvested at ZT0 or ZT12. 
Data represents mean ± stdev using pooled RNA assayed in triplicate. * p < 0.05, 
control vs. siUSP2.  
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reduced in response to RNAi knockdown of USP2 (Figure 3-3B). We conclude 
from these experiments that not only is USP2-45 a target of circadian signaling 
(Chapter 2) in the liver it also participates in diurnal regulation of glucose 
metabolism.  
 
3.2.3.  Hepatic overexpression of USP2 exacerbates glucose intolerance in 
diet-induced obese mice 
Hepatic gluconeogenesis and glucose secretion are elevated in diabetes 
and exacerbate hyperglycemia in diabetic states. We next examined whether 
USP2 expression is altered in the liver of high-fat diet fed (HFD) obese mice. 
Compared to lean control, mRNA expression of Usp2-45 is significantly 
decreased in the liver of diet-induced obese mice (Figure 3-4A). Chronic high-fat 
feeding results in obesity and hyperinsulineamia. Given that USP2-45 expression 
is suppressed by insulin in hepatocytes (Chapter 2), our results suggest that 
insulin may inhibit hepatic USP2-45 expression in obese mice, potentially serving 
as an adaptive mechanism to restrain hepatic gluconeogenesis when blood 
glucose is readily available and insulin levels are high.  
We next examined whether liver-specific overexpression of USP2 
exacerbates glucose intolerance in insulin resistant state. We transduced HFD-
fed mice with recombinant adenoviruses expressing GFP or USP2-45. 
Compared to control, blood glucose concentrations are significantly elevated in 
mice transduced with USP2-45 adenovirus under fed and fasted conditions 
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(Figure 3-4B). Fasting blood insulin concentrations are also significantly higher 
in mice transduced with USP2-adenovirus (Figure 3-4C). To rule out the 
possibility that enhanced glycogenolysis may contribute to elevated blood 
glucose in response to USP2-45; we measured liver glycogen content in 
transduced mice. Compared to GFP, USP2-45 significantly increases liver 
glycogen content (Figure 3-4D&E). In contrast, hepatic triglyceride content is 
modestly affected by USP2-45. Because gluconeogenesis is important for the 
indirect pathway of hepatic glycogen synthesis [27], these results suggest that 
USP2-45 augments gluconeogenic flux that leads to increased glucose 
production and glycogen storage. Glucose tolerance test (GTT) indicates that 
adenoviral-mediated overexpression of USP2-45 further impairs glucose 
tolerance in transduced mice (Figure 3-4F). Consistently, blood glucose levels 
remain significantly elevated at all time points in an insulin tolerance test (ITT) 
(Figure 3-4G).   
Analysis of serum samples also revealed a significant decrease in free 
fatty acid concentrations in USP2-45 mice in both fed and fasting conditions.  
Ketone bodies (fasting only) and serum triglycerides, however, remained similar 
in both groups (Table 3-1 & 3-2).  Interestingly, while body weights remain 
similar between both groups the liver weight to body weight ratios in USP2-45 
mice were significantly smaller compared to GFP control mice (Table 3-3).  One 
explanation for this could be changes in the level of macronutrients, like glycogen 
and triglycerides.  However, we observe no change in liver triglycerides, and  
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Figure 3-4. Hepatic USP2-45 overexpression promotes glucose intolerance 
in high-fat fed mice.  (A) qPCR analysis of hepatic USP2 gene expression in 
mice fed chow (filled) or high-fat diet (open). Data represents mean ± s.e.m (n=3). 
(B) Plasma glucose concentrations in HFD-fed mice transduced with GFP (open, 
n=7) or USP2-45 (filled, n=7) adenovirus. (C) Plasma insulin concentrations in ad 
lib transduced mice. (D) Liver glycogen and triglyceride content in transduced 
mice. (E) PAS stain of paraffin-embedded liver sections. (F) Glucose tolerance 
test in HFD-fed mice transduced with GFP (open diamonds, n=8) or USP2-45 
(filled squares, n=8) adenovirus. (G) Insulin tolerance test in transduced mice. 
For F&G data represents mean ± s.e.m. * p < 0.05, GFP vs. USP2-45. 
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Tables 3-1 – 3-3. Serum metabolites and other physiological characteristics 
of mice transduced with either GFP or UPS2-45 adenovirus.  Table 3-1 
Serum free fatty acid, ketone body, and cholesterol levels in fed and fasting 
states.  Table 3-2 Fasting serum triglyceride.  Table 3-3 Fed and fasting body 
weights, liver weight ratios (LW/BW), and white adipose tissue weight ratios 
(WATW/BW) at time of harvest.  Liver and white adipose weights are normalized 
to body weights.  Data represents mean ± s.e.m.  Fed group n = 8; fasted group 
n = 7.   * p < 0.05 GFP v. USP2-45. 
 
 
 
 
 
Table 3.1 Serum Free Fatty-Acids [mM] Ketone Bodies [nM] Serum Cholesterol [md/dL] 
Virus Fed Fast Fed Fast Fed Fast 
GFP 0.22 ± 0.011 0.613 ± 0.04 --- 0.734 ± 0.083 88.38 ± 2.3 97.07 ± 4.4 
USP2-45 0.18 ± 0.01*  0.46 ± 0.024* --- 0.648 ± 0.052 80.86 ± 2.2* 80.31 ± 2.9* 
Table 3.2 Free Glycerol [mg/dL] Total [mg/dL] Serum Triglycerides [mg/dL] 
Virus Fed Fast Fed Fast Fed Fast 
GFP 45.77 ± 2.2 54.71 ± 4.0 68.31 ± 3.6 101.26 ± 8.9 22.53 ± 3.0 46.55 ± 6.1 
USP2-45 40.65 ± 1.6 58.25 ± 4.6 65.92 ± 2.4 103.45 ± 10.8 25.28 ± 2.8 45.20 ± 7.9 
Table 3.3 Body Weight (g) LW/BW (%) WATW/BW (%) 
Virus Fed Fast Fed Fast Fed Fast 
GFP 35.1 ± 0.71 29.23 ± 4.89 ± 0.14 4.81 ± 0.41 4.11 ± 0.27 4.21 ± 1.2 
USP2-45 35.73 ± 0.69 30.20 ± 4.10 ± 0.10* 3.76 ± 0.24* 4.19 ± 0.32 5.24 ± 0.69 
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interestingly, an increase in glycogen content in USP2-45 livers.  As of yet this 
phenotype has yet to be explained. 
Analysis of hepatic gene expression indicates that PEPCK mRNA 
expression is significantly induced by USP2-45 (Figure 3-5A). Unlike chow-fed 
mice, the mRNA levels of G6Pase and G6PT1 are also increased in response to 
USP2-45 overexpression. Excess glucocorticoid signaling is responsible for the 
development of diabetes in patients with Cushing’s syndrome and has also been 
implicated in the pathogenesis of metabolic syndrome [28-31]. In humans, 
cortisone is released by the adrenal gland and converted to active cortisol locally 
in tissues by HSD1. A major physiological target of glucocorticoid signaling in the 
liver is gluconeogenesis; as such we postulated that USP2-45 might augment 
hepatic glucocorticoid signaling. In support of this, we found that mRNA levels for 
several known glucocorticoid target genes, including IGFBP1, TSC22D3, DUSP1, 
and ANGPTL4 [32], are also induced by USP2-45 in the liver.  While mRNA 
levels of CCL2, IL6, and TNFα, genes involved in inflammatory response, remain 
similar between two groups, the expression of several lipogenic genes, including 
fatty acid synthase (FAS), acetyl-CoA carboxylase 2 (ACC2), and glucokinase 
(GCK), appears to be enhanced by USP2-45 (Figure 3-5A).  Interestingly, both 
mRNA and protein levels of HSD1 are significantly increased in response to 
hepatic overexpression of USP2-45 (Figure 3-5B).  Increased HSD1 protein 
expression was confirmed using ImageJ software analysis (Figure 3-5C).  In 
contrast, the expression of Sec8, another ER membrane protein, and GR 
remains similar.  These results are consistent with elevated plasma insulin  
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Figure 3-5. Overexpression of USP2-45 in liver tissue increases expression 
of glucocorticoid responsive genes.  (A) qPCR analysis of liver gene 
expression in mice transduced with GFP (open) or USP2-45 (filled) adenovirus.  
Data represents mean ± s.e.m. * p < 0.05, GFP vs. USP2-45. (B) Immunoblotting 
analysis of total liver lysates from transduced mice as indicated. (C)  ImageJ 
quantitation of HSD1 protein levels in panel B normalized to Sec8 protein.  Data 
represents mean ± stdev. * p < 0.05, GFP vs. USP2-45.  
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concentrations in mice transduced with USP2-45 adenovirus.  In fact, the 
expression of SREBP1c, an insulin-responsive regulator of lipogenesis, is also 
induced by USP2-45 (Figure 3-5A).  AKT phosphorylation is modestly affected 
by USP2-45 showing increased pAKT-308 phosphorylation while the pAKT-473 
levels are similar between both groups (Figure 3-5B).  Together, these results 
demonstrate that USP2-45 augments glucocorticoid signaling in the liver and 
exacerbates glucose intolerance in insulin resistant state.  We next focused on 
whether USP2 deficiency in high-fat fed mice might have a beneficial affect on 
glucose tolerance.  
 
3.2.4.  Hepatic USP2 knockdown improves glucose homeostasis in obese 
mice 
The expression of USP2 is stimulated by starvation and reaches peak 
levels at the onset of dark phase (Chapter 2). Both of these conditions are 
characterized by active glucocorticoid signaling in the liver. As such, it is possible 
that USP2 plays an important role in modulating local glucocorticoid activation 
through its regulation of HSD1. We next examined whether RNAi knockdown of 
USP2 suppresses the gluconeogenic pathway and ameliorates glucose 
intolerance in HFD-fed mice. We transduced high-fat fed mice with scrambled 
(Scbl) or USP2 RNAi adenoviruses for 5-7 days. Compared to control, blood 
glucose levels are significantly lower in mice transduced with siUSP2 adenovirus 
when measured under ad lib and fasted conditions (Figure 3-6A). In addition, 
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fasting insulin concentrations are lower in the knockdown group (Figure 3-6B). 
Liver glycogen content is also reduced in mice transduced with siUSP2 
adenovirus, as revealed by quantitative assays and PAS staining (Figure 3-
6C&D). We next performed GTT and ITT in transduced mice to assess whole 
body glucose tolerance and insulin sensitivity. As shown in Figure 3-6E, blood 
glucose levels following an i.p. glucose bolus are significantly lower in mice 
transduced with siUSP2 adenovirus. Similarly, USP2 knockdown results in lower 
blood glucose levels following insulin injection (Figure 3-6F).  Extensive serum 
metabolite analysis also revealed elevated levels of free fatty acids and ketone 
bodies in fasted siUPS2 mice compared to controls (Table 3-4).  This could be 
compensation for decreased glucose output from the liver.  In addition, serum 
triglyceride content remained similar in each group (Table 3-5).  These results 
demonstrate that depletion of USP2 in the liver improves glucose homeostasis in 
insulin resistant state.   
Gene expression analysis reveals that RNAi knockdown of USP2 results 
in approximately 65% reduction in USP2 mRNA levels in the liver (Figure 3-7A). 
The expression of G6Pase and G6PT are decreased in response to USP2 
knockdown.  Surprisingly, PEPCK expression is only modestly affected, possibly 
as a result of lower insulin levels in mice transduced with siUSP2 adenovirus.  In 
addition, hepatic expression of TSC22D3 and DUSP1 are decreased following 
USP2 knockdown.  Interestingly, mRNA levels of IGFBP1 and ANGPTL4 remain 
unaltered by the treatments.  Compared to control, HSD1 mRNA (Figure 3-7A)  
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Figure 3-6. RNAi knockdown of USP2 in the liver ameliorates glucose 
intolerance in high-fat fed mice. (A) Plasma glucose concentrations in HFD 
mice transduced with control (filled, n=7) or siUSP2 (open, n=7) adenovirus. (B) 
Plasma insulin levels in transduced mice following overnight fasting. (C) Liver 
glycogen content in transduced mice. (D) PAS stain of paraffin-embedded liver 
sections. (E) Glucose tolerance test and (F) insulin tolerance test in mice 
transduced with control (filled diamonds) or siUSP2 (open squares) adenovirus.  
Data represents mean ± s.e.m. * p < 0.05, control vs. siUSP2. 
 
A C 
B
lo
od
 g
lu
co
se
 (m
g/
dL
) 
* 
* 
0 
30 
60 
90 
120 
150 
Fed Fasted 
0 
25 
50 
75 
100 
1" 2"
G
ly
co
ge
n 
co
nt
en
t 
(m
m
ol
 g
ly
co
sy
l r
es
id
ue
/g
) 
* 
siU
SP
2 
Sc
bl 
D 
E F 
0 
1 
2 
3 
1" 2"
In
su
lin
 (n
g/
m
l) 
siU
SP
2 
Sc
bl 
* 
0 
30 
60 
90 
120 
150 
0 20 40 60 80 100 120 
B
lo
od
 g
lu
co
se
 (m
g/
dL
) 
Minutes 
0 
100 
200 
300 
400 
500 
600 
0 20 40 60 80 100 120 
B
lo
od
 g
lu
co
se
 (m
g/
dL
) 
Minutes 
*"
Control 
siUSP2 
B 
Fe
d 
Fa
ste
d 
Scbl 
siUSP2 
*
"*"
*"
*"
*" *"
*"
GTT ITT 
Scbl 
siUSP2 
! 70!
 
Tables 3-4 – 3-6. Serum metabolites and other physiological characteristics 
of mice transduced with either Scbl or siUSP2 adenovirus.  Table 3-4 Serum 
free fatty acid, ketone body, and cholesterol levels in fed and fasting states.  
Table 3-5 Fasting serum triglyceride.  Table 3-6 Fed and fasting body weights, 
liver weight ratios (LW/BW), and white adipose tissue weight ratios (WATW/BW) 
at time of harvest.  Liver and white adipose weights are normalized to body 
weights.  Data represents mean ± s.e.m.  Fed group n = 7; fasting group Scbl, n 
= 6, siUSP2 n = 7.  * p < 0.05 Scbl v. siUSP2. 
 
 
 
 
 
Table 3.4 Serum Free Fatty-Acids [mM] Ketone Bodies [nM] Serum Cholesterol [md/dL] 
Virus Fed Fast Fed Fast Fed Fast 
Scbl 0.453 ± 0.031 0.568 ± 0.045 --- 0.702 ± 0.061 74.33 ± 3.9 86.05 ± 4.8 
siUSP2 0.510 ± 0.039 0.857 ± 0.062*  --- 1.071 ± 0.16*  73.79 ± 4.5 74.14 ± 3.2* 
Table 3.5 Free Glycerol [mg/dL] Total [mg/dL] Serum Triglycerides [mg/dL] 
Virus Fed Fast Fed Fast Fed Fast 
Scbl --- 51.42 ± 4.5 --- 103.69 ± 6.7 --- 52.27 ± 8.0 
siUSP2 --- 47.92 ± 3.0 --- 100.22 ± 10.3 --- 52.29 ± 10.4 
Table 3.6 Body Weight (g) LW/BW (%) WATW/BW (%) 
Virus Fed Fast Fed Fast Fed Fast 
Scbl 41.6 ± 0.62 26.80 ± 0.64 5.5 ± 0.22 5.01 ± 0.11 4.4 ± 0.19 2.71 ± 0.52 
siUSP2 41.9 ± 2.3 26.31 ± 0.44 5.2 ± 0.25 5.00 ± 0.11 4.3 ± 0.60 1.59 ± 0.18* 
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and protein levels are decreased in mice transduced with siUSP2 adenovirus 
(Figure 3-7B).  Decreased HSD1 protein expression in siUSP2 samples was 
confirmed using ImageJ software analysis (Figure 3-7C).  Again, while HSD1 
protein levels were decreased Sec8 and glucocorticoid receptor (GR) protein 
expression remains similar between both groups.  AKT phosphorylation at serine 
473 (pAKT-473) while inconsistent in the Scbl group does appear to be lower in 
the siUSP2 animals - while pAKT-308 levels appear similar between both groups 
(Figure 3-7B). We conclude from these studies that hepatic USP2 is required for 
maintaining normal levels of HSD1 expression and glucocorticoid action in the 
liver.  However, many question remain as to the exact mechanism by which 
UPS2-45 augments glucocorticoid signaling in liver tissue and its role in glucose 
output.  In the next 2 sections we lay out preliminary studies trying to answer 
those two questions.   
 
3.2.5.  USP2-45 is not sufficient to drive glucose secretion in primary 
hepatocytes 
We have now established that when we perturb USP2 levels in vivo, we 
see a drastic affect on glucose homeostasis.  We believe this effect primarily 
involves changes in glucose flux within the liver, however, we cannot rule out 
secondary effects by peripheral tissues such as skeletal muscle and white 
adipose tissue.  One way to address this concern is to determine whether USP2-
45 can drive glucose secretion in an isolated cell model.  We transduced 
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Figure 3-7. Knock-down of USP2 in liver tissue results in lower expression 
of HSD1 and several glucocorticoid responsive genes. (A) qPCR analysis of 
liver gene expression in HFD-fed mice transduced with control (filled) or siUSP2 
(open) adenovirus.  Data represents mean ± s.e.m. * p < 0.05, control vs. siUSP2. 
(B) Western blot analysis of total liver lysates from transduced mice. (C)  ImageJ 
quantitation of HSD1 protein levels in panel B normalized to Sec8 protein.  Data 
represents mean ± stdev. * p < 0.05, control vs. siUSP2.  
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primary hepatocytes with either a low or high dose of GFP control virus or USP2-
45.  Interestingly, at both concentrations USP2-45 had no effect on glucose 
secretion compared to control (Figure 3-8A).  We then infected primary 
hepatocytes with siUSP2 and looked at glucose secretion.  At this time it must be 
pointed out that the mRNA level of USP2-45 decreases significantly in isolate 
primary hepatocytes compared to liver tissue.  The cycle number (CT) for USP2-
45 in a real-time PCR assay is between 28-30 depending on the hepatocyte prep 
compared to a cycle number between 19-20 in liver tissue (Chapter 2).  We see a 
similar effect with gluconeogenic genes PEPCK and G6Pase as well as PGC-
1α (data not shown).  However, since we do not have a good antibody for USP2-
45 (Chapter 2) we cannot rule out the possibility that USP2-45 protein levels are 
significantly higher than mRNA levels would predict.  Under this reasoning we 
proceeded with transducing primary hepatocytes with Ad-siUSP2 and examine 
glucose secretion.  Similar to over-expression of USP2-45, transducing cells with 
siUSP2 (two doses) had no effect on glucose secretion compared to a scramble 
(Scbl) control virus (Figure 3-8B).  From this line of experiments, we conclude 
that USP2-45 is not sufficient to increase glucose secretion in vitro.  However, it 
is still unclear whether USP2-45 is required for proper glucose secretion in 
primary hepatocytes due to its low expression level in culture.   
To try to address this shortcoming we looked to increase glucose 
secretion by co-infecting hepatocytes with PGC-1α − a transcription factor known 
to regulate the gluconeogenic pathway both in vitro and in vivo [5, 33].  
Furthermore, since PGC-1α regulates USP2-45, we postulated that knockdown 
! 74!
of USP2 in the context of PGC-1α over-expression might yield a deficiency in 
PGC-1α's function – potentially providing a role for USP2-45.  We infected 
hepatocytes with either GFP or PGC-1α followed by a second infection with GFP 
or USP2-45.  Co-infection of GFP+USP2-45 showed no significant increase in 
glucose secretion while PGC-1α+GFP increased glucose secretion roughly 3 fold 
(Figure 3-8C).  In addition, co-infection of PGC-1α+USP2-45 yielded no 
significant increase in glucose output above that which PGC-1α+GFP already 
induced.  Next, to examine whether USP2 is required for PGC-1α induction of 
glucose secretion, we first infected cells with either GFP or PGC-1α followed by 
infection with either an Scbl control or an increasing dose of siUSP2.  Similar to 
Figure 3-8C, we saw roughly a 3-fold induction of glucose secretion from cells 
infected with PGC-1α compare to GFP control (Figure 3-8D).  However, we saw 
no impact on glucose secretion when we co-infected cells with PGC-1α+siUSP2 
(at both doses) compared to PGC-1α+Scbl wells.  To validate our co-infection 
model we looked at USP2-45 mRNA levels.  We observed roughly a 75% 
knockdown in USP2-45 mRNA levels in cells co-infected with PGC-1α+siUSP2 
compared to PGC-1α+Scbl control (Figure 3-8E).  From these experiments we 
conclude that at least in our primary hepatocyte culture model, USP2-45 alone or 
in co-infection experiments with PGC-1α is not sufficient to augment glucose 
output.  It also appears as though in respect to PGC-1α’s ability to increase 
glucose secretion, USP2-45 is dispensable as well.  However, since we see such  
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Figure 3-8.  Overexpression or knock-down of USP2-45 does not disrupt 
glucose secretion in mouse primary hepatocytes.  (A) Measurement of 
glucose secretion in primary hepatocytes transduced with a low or high dose of 
Ad-GFP or Ad-UPS2-45 or (B) with Ad-Scrbl (scramble) or Ad-siUSP2.  Glucose 
secretion in primary hepatocytes co-infected with either (C) PGC-1α and USP2-
45 or (D) PGC-1α and siUSP2.  Glucose secretion assays were run in duplicate 
wells for A-D and normalized to protein content within each well using Bradford 
method.  Data represents mean ± stdev.  * = p < 0.05.  (E) USP2-45 mRNA 
expression in samples co-infected with Ad-Scrbl and Ad-PGC-1α or Ad-siUSP2 
and Ad-PGC-1α.  Samples were run in duplicate and represent the mean ± stdev.  
* = p < 0.05.  
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a strong phenotype in vivo, it could be that primary hepatocytes do not 
adequately model the complexity of liver tissue.   
 
3.2.6.  HSD1 is de-ubiquitinated by USP2-45 In Vitro  
Our model so far for UPS2-45’s action on glucose homeostasis in liver 
tissue is the localized increase in glucocorticoid signalling via increases in both 
mRNA and protein levels of HSD1.  Since other papers point to USP2’s (both 
USP2-45 and USP2-69) role in post-translational modification of proteins, we 
wondered whether HSD1 was also a target of USP2-45.  However, we first 
needed to establish whether HSD1 is ubiquitinated as there are no published 
reports showing such data.  To this end we transfected either Flag-tagged 
ubiquitin (Flag-Ub) or HA-tagged HSD1 (HA-HSD11β1) separately, or in 
combination, in Ad293 cells.  We then immuno-precipitated with anti-HA beads 
and blotted against Flag.  Surprisingly, when Flag-Ub and HA-HASD11β1 were 
transfected in the same well we observed both mono- and poly-ubiquitinated 
HSD1.  The presence of poly-ubiquitinated species suggested HSD1 is a target 
of proteasomal degradation.  Indeed, when we treated co-transfected cells with 
proteasomal inhibitors, MG132 and PS341, we observed an increase in levels of 
poly-ubiquitinated HSD1 (Figure 3-9A).  In contrast, over-expression of wild-type 
USP2-45 decreased ubiquitination of HSD1 in a dose dependent manner. 
Inclusion of a catalytically dead USP2-45, USP2-45 H348A, had not effect on 
ubiquitin levels of HSD1.   
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Figure 3-9.  USP2-45 de-ubiquitinates HSD1 in vitro.  (A) Ad293 cells were 
co-ntransfected with either Flag-tagged Ubiquitin (Flag-Ub) or HA-tagged HSD1 
or in combination.  Samples were then immune-precipitated using anti-HA beads 
and immune-blotted with anti-Flag.  Samples were also treated with proteasomal 
inhibitors MG132 and PS341 - poly-ubiquitination schematic to right of western 
blot.  (B) Ad293 cells were transfected with different combinations of Flag-Ub, 
HA-HSD1, USP2-45 (WT) and USP2-45 (H348A) – WT and H348A were titrated 
into transfected cells.  Sample lysates were then immuno-precipitated with anti-
HA beads and immno-blotted using anti-Flag.  An anti-tubulin antibody was used 
to control for protein loading. 
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We next sought to identify potential lysine residues responsible for 
ubiquitination of HSD1.  The HSD1 protein is intrinsic to the ER membrane, 
containing a short five-amino acid (M-A-V-M-K) cytosolic domain, followed by a 
single transmembrane domain, and a catalytic domain located in the ER lumen 
(Figure 3-10A) [34].  The lysine residue in the cytosolic domain presents and 
interesting candidate because of its localization as well as it being conserved in 
other species including; guinea pig, rabbit, rat, monkey and humans.  However, 
loss of this lysine (HSD1 K5R) did not result in loss of ubiquitination in co-
transfection experiments with Flag-tagged Ub (Figure 3-10B).  We conclude 
from these experiments that HSD1 is indeed ubiquitinated, at least in vitro, and 
does not depend on the conserved lysine residue in the cytosolic domain.  We 
also demonstrate that USP2-45 over-expression results in deubiquitination of 
HSD1.  However, what role this has on HSD1 function or stability remains to be 
determined.    
 
3.2.7 Inhibition of HSD1 by CBX blocks the stimulatory effects of USP2-45 
on hepatic gluconeogenesis 
To directly assess the significance of HSD1 in mediating the effects of 
USP2-45 on glucose metabolism, we transduced HFD fed mice with GFP or 
USP2-45 adenoviruses followed by subcutaneous injection of saline or 
carbenoxolone (CBX, 40 mg/kg), an inhibitor of HSD1. Chronic CBX treatments 
have been previously demonstrated to improve glycemic control in rodents and 
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Figure 3-10.  Cytosolic lysine residue in HSD1 is not required for 
ubiquitination.  (A) Schematic of HSD1 localization in the ER membrane.  
HSD1 contains a catalytic domain localized in the ER lumen with a single 
transmembrane domain and a 5-amino acid cytosolic domain.  (B) Ubiquitination 
assay with cells transfected with either: Flag-Ub, HA-HSD1 WT, HA-HSD1 K5R - 
or in combination.  Samples were immuno-precipitated with anti-HA beads and 
blotted against Flag.  Samples were also blotted against HSD1 to ensure similar 
protein levels.    
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humans [35-37]. As expected, adenoviral-mediated expression of USP2-45 
significantly elevates circulating glucose and insulin concentrations (Figure 3-
11A). While daily injections of CBX for three days have modest effects on blood 
glucose levels in control mice, these treatments nearly abolished the 
hyperglycemic effects of USP2-45. Plasma insulin levels are also decreased by 
CBX in mice with hepatic overexpression of USP2-45. Further, the augmentation 
of liver glycogen accumulation in response to USP2-45 is significantly blocked by 
CBX treatments (Figure 3-11B). Analysis of hepatic gene expression indicates 
that the induction of PEPCK and G6Pase by USP2-45 is significantly diminished 
by HSD1 inhibition, while surprisingly G6PT1 remains unaltered (Figure 3-11C).     
Body weights were similar between all four groups of mice (Table 3-7).  
However, the liver weights (LW/BW) for USP2-45 (PBS) and USP2-45 (CBX) 
mice were significantly smaller than that of GFP (PBS) mice.  This phenotype 
was observed in earlier experiment (Section 3.23). Serum metabolite analysis 
reveals no significant changes in cholesterol (Table 3-8) or free fatty-acid (Table 
3-9) levels.  However, we do observe a significant decrease in free glycerol 
levels in USP2-45 (PBS) mice compared to GFP (PBS) mice, which might 
indicate less lipolysis in white adipose tissue – this would fit as USP2-45 (PBS) 
mice have significantly higher insulin levels (Table 3-10).  White adipose tissue 
weight (WATW/BW) while elevated in USP2-45 (PBS) mice, does not reach 
significant levels compared to GFP (PBS) mice.  
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Figure 3-11. HSD1 inhibition blocks the effects of USP2-45 on glucose 
metabolism. (A) Plasma glucose and insulin concentrations and (B) liver 
glycogen content in mice transduced with GFP (open, n=6) or USP2-45 (filled, 
n=6) followed by treatments with vehicle or CBX for 3 days. Data represents 
mean ± s.e.m. * p < 0.05 USP2-45 vs. GFP; # p < 0.05 CBX vs. PBS. (C) qPCR 
analysis of liver gene expression. Data represents mean ± stdev using pooled 
RNA samples assayed in triplicate. 
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Tables 3-7 – 3-10. Serum metabolites and other physiological 
characteristics of mice treated with CBX.  Table 3-7 Body weights, liver 
weights (LW/BW) and white adipose tissue weights (WATW/BW) at time of 
harvest of mice transduced with GFP or USP2-45, followed by a 3d treatment 
with vehicle or CBX. Liver and white adipose weights are normalized to body 
weights.  Table 3-8 Serum cholesterol levels at time of harvest.  Table 3-9 
Serum free fatty-acid levels at time of harvest.  Table 3-10 Serum triglyceride 
levels at time of harvest.  Data represents mean ± s.e.m. * p < 0.05 USP2-45 vs. 
GFP; # p < 0.05 CBX vs. PBS. 
 
 
 
 
 
 
 
Virus Treatment Free Glycerol        [mg/dL] Total [mg/dL] TGs [mg/dL] 
GFP PBS 55.3 3.0 92.32.0 37.0 3.3 
GFP CBX 52.1 2.6 98.1 5.4 46.0 5.4  
USP2-45 PBS 46.2 2.8* 79.0 3.2* 32.7 1.6 
USP2-45 CBX 51.2 3.4 102.4 4.2*#  51.1 5.3*# 
Table 3.10 
Virus Treatment Body Wt. (g) LW/BW (%) WATW/BW (%) 
GFP PBS 41.6 1.08 5.82 0.34 4.57 0.46 
GFP CBX 41.3 1.18 6.15 0.47 4.16 0.51 
USP2-45 PBS 41.9 0.79 4.36 0.35* 4.99 0.50 
USP2-45 CBX 42.0 0.73 4.59 0.34* 4.89 0.37 
Table 3.7 
Virus Treatment Cholesterol  [mg/dL] 
GFP PBS 158.8 13.07 
GFP CBX 149.4 14.2 
USP2-45 PBS 155.8 17.4 
USP2-45 CBX 141.1 9.55 
Table 3.8 
Virus Treat FFAs [mM] 
GFP PBS 0.511 0.035 
GFP CBX 0.454 0.033 
USP2-45 PBS 0.484 0.031 
USP2-45 CBX 0.560 0.053 
Table 3.9 
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Together, these results strongly suggest that the activation of 
glucocorticoid signaling through HSD1 is critical for mediating the metabolic 
effects of USP2-45 on hepatic gluconeogenesis and glucose production.  
However, we cannot exclude off target effects of CBX, since it was administered 
systemically, and more experiments are needed to solidify this inference.    
 
3.3.  Conclusions 
1.) USP2 is sufficient and necessary for maintaining proper fasting  
     gluconeogenic activity through augmentation of hepatic glucocorticoid  
     signaling.  
2.) In high-fat diet fed mice, over-expression of USP2-45 exacerbates glucose  
     intolerance and insulin resistance.  In contrast, knockdown of USP2 in liver  
     tissue ameliorates glucose intolerance in similar HFD experiments. 
3.) HSD1 induction is required for mediating USP2’s effect on hepatic glucose  
     metabolism. 
 
3.4.  Discussion  
Hepatic gluconeogenesis is increased in response to starvation and is 
critical for maintaining a steady supply of glucose for tissues that rely on glucose 
! 84!
for energy production. Glucocorticoids and glucagon are major counter-
regulatory hormones that stimulate gluconeogenic gene expression and hepatic 
glucose production. In mammals, diurnal feeding cycles also provide 
physiological cues that modulate hepatic glucose and lipid metabolism. In fact, 
the expression of a large number of genes involved in nutrient and energy 
metabolism is highly rhythmic in rodent livers [8, 38, 39]. The mechanisms that 
integrate these hormonal and circadian signals in the regulation of 
gluconeogenesis are poorly understood. Here, we identified USP2-45 as a 
deubiquitinase capable of regulating hepatic gluconeogenesis and glucose 
homeostasis through modulating glucocorticoid signaling in the liver.  
In vivo gain- and loss-of-function studies demonstrate that USP2 is 
sufficient and necessary for maintaining normal gluconeogenic activity in the 
liver. Tail vein injection of recombinant adenovirus expressing USP2-45 leads to 
elevated blood glucose and insulin concentrations. Direct assessment of hepatic 
gluconeogenesis using pyruvate as a substrate indicates that USP2-45 
significantly increases hepatic glucose production.  However, over-expression of 
USP2-45 in primary hepatocytes did not increase glucose output suggesting 
other factors are needed for USP2-45 action on glucose homeostasis.  
Conversely, our primary hepatocyte model might not be adequate to elucidate 
the effect USP2-45 has on glucose homeostasis in liver tissue.  In contrast, 
depletion of endogenous USP2 by in vivo RNAi knockdown impairs 
gluconeogenic gene expression and results in the development of hypoglycemia 
during fasting. USP2 deficiency in the liver also perturbs normal diurnal glucose 
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rhythms under restricted feeding conditions (Figure 3-3).  In HFD-fed mice, 
adenoviral-mediated expression of USP2 exacerbates glucose intolerance and 
insulin resistance, as illustrated by elevated blood glucose and insulin levels.  In 
this case, hepatic USP2-45 overexpression impairs the ability of transduced mice 
to clear glucose from circulation during GTT.  While it is possible that impaired 
response to insulin is local in nature, i.e. suppression of gluconeogenesis in the 
liver, we cannot rule out the possibility that other tissues, such as skeletal muscle 
and white adipose tissue, may also develop insulin resistance secondary to 
hepatic insulin resistance.  Accordingly, RNAi knockdown of USP-2 ameliorates 
glucose intolerance in diet-induced obese mice.  As such, USP2-45 appears to 
serve as a “rheostat” in the liver that adjusts hepatic gluconeogenesis and 
glucose output.   
Perhaps the most intriguing aspect of USP2 regulation of hepatic 
gluconeogenesis is its role in modulating HSD1 expression. Hepatic 
overexpression of USP2-45 increases HSD1 mRNA and protein levels, leading to 
the induction of gluconeogenic genes as well as several other glucocorticoid 
targets, whereas RNAi knockdown of USP2 significantly lowers HSD1 gene 
expression in the liver.  Also it appears HSD1 is a target of ubiquitination and that 
USP2-45 can modulate this affect.  What role that level of regulation plays in 
HSD1 function or stability still remains to be explored.  More importantly, 
chemical inhibition of HSD1 activity by CBX abolished the ability of USP2-45 to 
activate gluconeogenic genes and raise blood glucose levels, suggesting that 
HSD1 induction is required for mediating the effects of USP2 on glucose 
! 86!
metabolism.  
 
3.5.  Future Directions 
3.5.1.  Increased hepatic gluconeogenesis through USP2-45 
 Over expression of USP2-45 led to an increase in glucose output when 
mice were challenged with a bolus of pyruvate.  In contrast knockdown of USP2 
caused a significant decrease in glucose output in a similar pyruvate challenge.  
However, we also observed significant changes in plasma insulin concentrations, 
especially in USP2-45 over-expression mice.  While a PTT and ITT can give 
good estimates for hepatic glucose output and insulin sensitivity they are not the 
gold standard in the metabolic field.  A better way to address this question would 
be to employ a hyperinsulinemic euglycemic clamp study.  This will enable us to 
better measure hepatic glucose output as well as systemic insulin sensitivity 
while maintaining constant insulin levels.    
3.5.2.  Glucocorticoid signalling 
 Glucocorticoid signalling has been shown to affect the gene expression 
levels of gluconeogenic genes such as PEPCK and G6Pase [40].  In our studies 
USP2-45 augments gene expression of glucocorticoid responsive genes PEPCK 
and G6Pase, as well as HSD1, IGFBP1 and TSC22D3.  Glucocorticoid receptor 
levels do not change in whole cell lysates in either USP2-45 over expression or 
siUSP2 knockdown experiments; however one thing we have yet to look at is GR 
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localization.  Upon ligand binding GR translocates to the nucleus to drive mRNA 
transcription.  One way to look at GR localization would be to isolate nuclei from 
liver tissue and look at GR content.  If USP2-45 is increasing glucocorticoid 
signalling then we should see an increase in GR nuclear localization.    
 In addition, previous work has demonstrated insulin resistance and obesity 
are not associated with systemic increases in glucocorticoid levels but rather 
local ligand activation via increased activity of HSD1 [41].  In this chapter we 
postulated that over-expression of USP2-45 augments glucocorticoid signalling 
by increasing expression of HSD1.  This is supported by increases in GC 
response genes as well as amelioration of USP2-45 hyperglycemia when HSD1 
is chemically inhibited (CBX).  However, whether HSD1 enzymatic activity, and 
therefore glucocorticoid activation is actually enhanced in USP2-45 mice remains 
unknown.  HSD1 enzymatic activity could be analysed using isolated liver 
microsomes from USP2-45 over-expression mice or siUSP2 mice – measuring 
the rate of conversion of [3H] corticosterone to 11-dehydrocorticosterone.  This 
would be a definitive method showing an increase in HSD1 activity and 
glucocorticoid signaling. 
3.5.3.  Ubiquitination of HSD1  
 For the first time we demonstrate that HSD1 is ubiquitinated, in vitro.  
However, what role ubiquitination plays in HSD1 function or stability still remains 
unknown.  Initial results suggest HSD1 is poly-ubiquitinated and the USP2-45 is 
able to reverse this process.  The poly-ubiquitination suggests that HSD1 is 
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targeted for degradation by the proteasomal machinery – proteasomal inhibitors 
also increased this poly-ubiquitination.  We posit that USP2-45 maybe playing a 
role in HSD1 stability.  One way to address this inference is using pulse-chase 
assays in co-transfection experiments with HSD1, USP2-45 WT and USP2-45 
H348A and looking at HSD1 stability.  How this fits in with our model still remains 
to be seen and more experiments are required to address all these questions.   
  
3.6.  Materials and Methods 
Cultured primary hepatocytes. Primary hepatocytes were isolated from 
C57/Bl6J mice using collagenase type-II (Invitrogen), as previously described 
[42]. Hepatocytes were maintained in Dulbecco Modified Eagle Medium (DMEM) 
supplemented with 10% bovine growth serum (BGS) and antibiotics at 37oC and 
5% CO2. For adenoviral transduction, recombinant adenoviruses were generated 
using AdEasy adenoviral vector (Stratagene) as previously described [43]. 
Hepatocytes were transduced for 48 hrs at similar moiety of infection before RNA 
isolation and gene expression analysis.  RNAi sequences are as follows;  siUSP2 
#1 CGACAGATGTGGAGGAAGT; siUSP #2 AGACCCAGATCCAGAGATA. 
  
Glucose Secretion Assay.  Primary hepatocytes were cultured as previously 
described above.  Virus was transduced in primary hepatocytes for 48hrs prior to 
glucose secretion assay.  For co-infection experiments primary hepatocytes were 
transduced with viruses in series.  Primary hepatocytes were infected with the 
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first virus for 1hr, washed with media, and then transduced with second virus for 
1hr – cells were again washed and fresh media added.   After 48hrs cells were 
washed with cold 1x PBS three times and placed on gluconeogenic media 
(phenol red free DMEM, 10mM sodium pyruvate, 2mM D-Lactate).  After 3hrs 
quantification of glucose secretion was analyzed using a Glucose 
Oxidase/Peroxidase Reagent and o-Dianisidine (Sigma) followed by spectral 
analysis at 540nm.  Cells were again washed twice with 1x PBS and incubated 
with Flag lysis buffer on ice for 30 minutes.  Protein concentrations from cell 
lysates were measured using Bradford reagent (BioRad).  
 
Gene expression analysis. Total liver or hepatocyte RNA was isolated using 
Trizol (Invitrogen), reversed transcribed using MMLV reverse transcriptase, and 
analyzed by quantitative PCR using Sybr Green method. The primers used for 
qPCR analysis are listed:  Tsc22d3 (Fwd 5’- cctcaacactgacaagctgaac; Rev 5’- 
gagcatggtctggtctatgttg), Angptl4 (Fwd 5’- gactcagctcaaggctcaaaac; Rev 5’- 
ttcccctcgaagtcttgtctac), Dusp1 (Fwd 5’- gatcctgtccttcctgtacctg; Rev 5’- 
gtgaccctcaaagtggttagga), HSD1 (Fwd 5’- ggaggaaggtctccagaaggt; Rev 5’- 
agagacagcgaggtctgagtg), TNFα (Fwd 5’- agcccccagtctgtatcctt; Rev 5’- 
ctccctttgcagaactcagg), CCL2 (Fwd 5’- aggtccctgtcatgcttctg; Rev 5’- 
tctggacccattccttcttg), IL6 (Fwd 5’- agttgccttcttgggactga; Rev 5’- 
tccacgatttcccagagaac) or described in previous studies [5, 43]. 
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In vivo mouse studies. C57BL/6J mice were kept on a 12:12 light-dark cycle 
with food and water freely available. For fasting/refeeding studies, mice were 
provided food ad lib, fasted for 20 hrs, or refed for 18 hrs following fasting. 
Tissues were harvested at the same time and frozen immediately for gene 
expression analysis. For in vivo adenoviral transduction, chow or high-fat fed 
male mice were injected via tail vein purified adenoviruses at approximately 0.15 
OD per mouse. Metabolic studies and gene expression analysis were performed 
5-7 days following tail vein injection. The expression of GFP and adenoviral gene 
AdE4 was monitored to ensure similar doses were administered. For 
carbenoxolone treatments, high-fat diet transduced mice were subcutaneously 
injected with either saline or 40 mg/kg of body weight or CBX once daily for 3 
consecutive days between 11am and 12pm. Bmal1 flox/flox mice were obtained 
from the Jackson Laboratory. Liver-specific Bmal1 knockout mice were 
generated by breeding the flox/flox mice with Albumin-Cre transgenic mice. 
Tissues were harvested every 3 hrs for a period of 24 hrs for gene expression 
studies.  The University Committee on Use and Care of Animals (UCUCA) at the 
University of Michigan approved all animal procedures performed in this paper.  
 
Pyruvate, insulin, and glucose tolerance tests. For insulin tolerance test, 
transduced high-fat diet fed (10-12 weeks) mice were placed in clean cages 
without food for 4-5 hours and injected i.p. with an insulin solution at 0.8 units/kg 
of body weight.  Blood glucose levels were measured before insulin injection and 
20, 40, 60, and 120 minutes after injection. For glucose tolerance test, 
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transduced high-fat diet fed mice were fasted overnight and injected i.p. with 
glucose (2g/kg, in 0.9% NaCl). Blood glucose levels were measured before 
injection and at 20, 40, 60 and 120 minutes after glucose injection. For the 
pyruvate tolerance test, transduced chow fed mice were fasted over-night (~16 
hrs) and injected i.p. with 2g/kg of body weight of sodium pyruvate starting at 
9am.  Blood glucose levels were measured before injection as well as 20, 40, 60, 
and 120 minutes post injection. 
 
Liver glycogen measurements. Liver glycogen levels were measured as 
previously described [44].  Briefly, a small piece of liver (30-60 mg) was weighed 
and boiled at 98.5oC in 30% KOH for 30 minutes with occasional vortexing. Then 
1M NaSO4 was added to reaction and thoroughly mixed followed by addition of 
100% ethanol to precipitate glycogen.  Samples were heated briefly and 
centrifuged at 13,000rpms for 5 minutes at room temperature.  Pellets were 
resuspended in ddH2O and treated with 100% ethanol followed by a 13,000rpm 
spin for 5 minutes at room temperature (this process was done twice).  The pellet 
was allowed to dry over night before treatment with amyloglucosidase 
(0.25mg/ml in 0.2M NaOAc, pH4.8). Treatment with amyloglucosidase was 
allowed to proceed for 3hrs.  Quantification of glucose release was analyzed by 
using a Glucose Oxidase/Peroxidase Reagent and o-Dianisidine (Sigma) 
followed by spectral analysis at 540nm. 
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Histology. Liver tissue from transduced mice were fixed in 4% 
paraformaldehyde and processed for paraffin embedding.  Paraffin embedded 
liver sections were stained for glycogen using Schiff’s Periodic Acid Staining 
(PAS) Kit (Polysciences, Inc).    
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Notes 
Portions of this work were included in a paper in preparation entitled:  “Ubiquitin-
specific protease 2 regulates hepatic gluconeogenesis and diurnal glucose 
metabolism through 11β-hydroxysteroid dehydrogenase 1,” Matthew M. Molusky, 
Siming Li, Di Ma, Lei Yu, and Jiandie D. Lin. 
M. M. Molusky and J. D. Lin designed the experiments and prepared the 
manuscripts.  S. Li and L. Yu were responsible for the HSD1 ubiquitination 
assays as well as the protein blotting in Figures 3-5 & 3-7.   
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Chapter 4 
 
Localization of UPS2-45 to the peroxisome in primary 
hepatocytes 
 
4.1.  Introduction 
Peroxisomes, or microbodies, are single membrane-bound organelles 
found in virtually all higher and lower order eukaryotes.  First described in mouse 
kidney cells, as circular or spherical organelles, peroxisomes are involved in a 
wide array of biochemical pathways [1].  Central of which are oxidation of fatty 
acids (FAs) (both α- and β-oxidation) and detoxification of hydrogen peroxide.  In 
fact, compartmentalization of catalase, an enzyme involved in hydrogen peroxide 
(H2O2) breakdown, along with H2O2 producing enzymes is how this organelle 
derived its name.  Additionally, in humans, peroxisomes serve a role in the 
! 98!
synthesis of cholesterol (although there is some debate about this), bile acids, 
and plasmogens [2].     
Peroxisomes can vary significantly in size and enzymatic content, 
corresponding to organism, cell type, tissue type and metabolic demand.  
However, one pathway that seems to be universal from tissue to tissue and from 
organism to organism is fatty acid oxidation.  In lower eukaryotic species like 
yeast, FA β-oxidation is solely accomplished by peroxisomes, while in humans 
and other higher order eukaryotes the role is shared between peroxisomes and 
mitochondria [2].  In this case peroxisomes play a critical role in lipid metabolism 
that is not performed by mitochondria.  While short-, medium- and long-chain 
(predominantly) FAs are metabolized in the mitochondria, very long-chain fatty 
acids (VLCFAs), notably 24:0 and 26:0, can only be handled by peroxisomes.  
Other types of FAs that rely on peroxisomal β-oxidation include; branched-chain 
fatty acids (BCFAs), like pristanic acid, long-chain polyunsaturated fats as well as 
bile acid intermediates dihydroxycholestanoic acid (DHCA) and 
trihydroxycholestanoic acid (THCA).  While peroxisomes contain a full array of β-
oxidation machinery, most FAs species go through several rounds of α- or β-
oxidation, and then, the intermediates are transported to the mitochondria and 
oxidized to completion [3].  
Peroxisomes lack protein-encoding genetic material and therefore must 
have proteins imported, post-translationally, into pre-existing peroxisomes.  
Unlike other translocation machinery, (eg the ER and mitochondria), 
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peroxisomes are able to facilitate transport of folded even oligomeric protein 
complexes across the membrane and into the peroxisome matrix.  The finer 
points of this translocation still remain a mystery, however, in general it can be 
thought of as a cycling-receptor system where cargo attaches to a cytosolic 
receptor, translocates to the peroxisome matrix where the cargo is released and 
the receptor is cycled back to the cytoplasm.  This mechanism is dependent on 
both ATP and ubiquitin for import and receptor recycling.  Two peroxisomal 
targeting sequences, termed PTS1 and a less frequently used PTS2 have been 
characterized.  The PTS1 is a tri-peptide motif found in the C-terminus with a 
consensus sequence of (S/A/C)-(K/R/H)-(L/M).  While the PTS2 nona-peptide 
motif is found in the N-terminus of target proteins, with a consensus sequence of 
(R/K)-(L/I/V)-X5-(Q/H)-(L/I/V).  In each instance target proteins bind to one of two 
soluble cognate receptors, PEX5 for PTS1 and PEX7 for PTS2, facilitating import 
across the peroxisome membrane [1].  These soluble receptors are then recycled 
back to the cytosol to bind with other cargo. 
The importance of peroxisomes can be highlighted by an array of genetic 
diseases that are associated with peroxisomal dysfunction.  One of the most 
notable is Zellweger Syndrome (ZS), a peroxisome biogenesis disorder (PBD), 
which results in complete absence of peroxisomes in patients.  It is characterized 
by impaired brain development, craniofacial abnormalities and liver dysfunction, 
resulting in a life expectancy of less than a year.  Other notable diseases include 
X-linked adrenoleukodystrophy (X-ALD), which results in impaired β-oxidation 
and Refsum disease, which results in impaired α-oxidation and build up of toxic 
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BCFAs, like phytanic acid.  Many of these diseases demonstrate an increase in 
circulating VLCFAs underlying the importance of peroxisomes in fatty acid 
oxidation.  
    
4.2.  Results 
4.2.1.  In Silico approach to looking at USP2-45 localization 
Localization or compartmentalization is one way in biology to segregate 
enzymatic function and create specificity.  To identify where USP2-45 might 
localize in the cell we employed an in silico approach.  We felt this might elicit a 
rapid dissemination of information allowing us to narrow down our field of 
experiments.  We used the PSORTII (freely available at ExPASy.com) program 
developed by Horton & Nakai [4].  This prediction model considers nuclear, 
cytoplasmic, endoplasmic reticulum (ER) and peroxisomal localization among 
others for eukaryotic proteins.  What this prediction model demonstrated was 
USP2-45 contains a PTS1 (-SRM) motif in the C-terminus of the protein.  Also, 
since USP2-45 and USP2-69 share a common C-terminal (Chapter 2), USP2-69 
also contains this PTS1 motif (-SRM).  We next determined whether this was 
unique to USP2 or whether other USP family members also contained a PTS1 
motif.  To this end we employed a PTS1 prediction program developed by 
Eisenhaber et al [5].  This prediction model took into account not only the C-
terminus tri-peptide motif, but also nine upstream residues critical for signal 
recognition by PEX5 (See Introduction).       
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Figure 4-1  In silico  peroxisomal targeting sequence 1 (PTS1) screen for all 
annotated ubiquitin specific proteases (mouse).   The PTS1 predictor 
program developed by Neuberger G et al. was used to identify USP family 
members harboring a C-terminal PTS1 motif.  Known PTS1 containing proteins 
(and peroxisomally located) catalase, ECH1, and EHHADH were used as 
positive controls. 
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For this in silico screen we used all annotated mouse USP family 
members as well as catalase, enoyl coenzyme A hydratase 1 (ECH1) and enoyl-
Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase (EHHADH) 
as positive controls for PTS1 motifs.  We then plotted the score the query 
received (positive score correlates with possible peroxisomal targeting and 
negative score correlates with no peroxisomal targeting) versus an arbitrary 
number assigned to the USP family member.  USP2 received a positive score 
with an identifiable PTS1 motif suggesting peroxisomal targeting.  Interestingly, 
no other USP family member received a positive score, suggesting this PTS1 
motif is unique to USP2.  Also, all three positive controls catalase, ECH1, 
EHHADH were predicted to be peroxisomal giving us some confidence in the 
prediction model.  We conclude from these experiments that USP2 does contain 
a PTS1 motif and that USP2 is possibly localized to the peroxisome.  We next 
sought to confirm our in silico results by physically looking at USP2-45 
localization using immunofluorescence.   
 
4.2.2 USP2-45 localizes to the peroxisome in primary hepatocytes 
While USP2-45 (and USP2-69) contains a consensus PTS1 tripeptide 
motif (-SRM) this does not necessarily mean USP2-45 is truly peroxisomal.  This 
can be demonstrated by mevalonate kinase (MK) and a bile acid conjugating 
enzyme, BATT, containing a PTS1 motif,, yet are localized to the cytoplasm [2, 
6].  To confirm our in silico results we looked at USP2-45 localization in primary  
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Figure 4-2.  USP2-45 co-localizes with catalase, a peroxisomal marker, in 
primary hepatocytes.  Immunofluorescent confocal microscopy of primary 
hepatocytes infected with Ad-USP2-45 and stained for anti-flag, DAPI and either 
anti-catalase (A), Mitotracker (B) or anti-lamp2 (C).  Alexaflour (Invitrogen) 
secondary antibodies were used in anti-flag and anti-lamp2 images.  All three 
images are merged in far-right column (merged).  
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hepatocytes using immunofluorescence confocal microscopy.  When we used 
catalase as a marker for peroxisomes we found that it co-localized with flag-
tagged USP2-45 (Figure 4.2A, Merged).  When we looked at markers for 
mitochondria (Figure 4.2B) and endosomes (Figure 4.2C) we found no co-
localization with USP2-45.  Cells were counterstained with DAPI.  This suggests 
that USP2-45 is indeed a bona-fide peroxisomal target.  We next chose to 
interrogate the requirement for USP2-45’s PTS1 motif for peroxisomal targeting.   
The PTS1 motif is a cis-acting sequence required for a majority of 
peroxisomal protein import.  Gould et al. demonstrated early on the sufficiency 
and necessity of this tripeptide motif [7].  To test whether the PTS1 signal is 
crucial for USP2-45 localization we employed site-directed mutagenesis – 
utilizing a two-prong approach.  We either mutated the serine in the number 1 
position (-SRM) to a glutamic acid (S394E), or we inserted a premature stop 
codon at the serine position (S394Stop), removing the PTS1 entirely.  Again, we 
employed immunofluorescent confocal microscopy to visualize localization of our 
PTS1 mutant constructs.  As anticipated in both cases we observed a 
cytoplasmic localization for the USP2-45 S394 (Figure 4.3, middle row) and 
USP2-45 S394Stop (Figure 4.3, lower row) mutants compared to wild-type 
USP2-45  (Figure 4.3, upper row), which co-localizes with our peroxisomal 
marker, catalase (merged column).  Slides were counter-stained with DAPI.  This 
suggests that USP2-45’s PTS1 motif is required for peroxisomal import, further 
confirming our previous results.  
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Figure 4-3. Disruption of PTS1 in USP2-45 causes cytoplasmic distribution 
in primary hepatocytes.  Flag-tagged wild-type (upper), S394E mutant (middle), 
or S394Stop mutant (lower) USP2-45 constructs were transfected in to primary 
hepatocytes.  Cells were fixed and permialized and stained with DAPI (left), anti-
catalase (middle left), anti-flag (middle right).  All three images are merged on far 
right. 
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4.3.  Conclusions 
1.) USP2-45 contains a peroxisomal targeting sequence (PTS1) and is localized  
      to the peroxisome in primary hepatocytes 
2.) The PTS1 motif is required for proper USP2-45 localization.  
 
4.4.  Discussion 
In mammals, roughly 50 enzymes have been identified as peroxisomal, 
involving several different metabolic pathways including, polyamine and oxygen 
metabolism, FA α- and β-oxidation, as well as plasmogen biosynthesis.  Our in 
silico experiments revealed USP2-45 (and USP2-69) to contain a PTS1 motif, 
and that this motif was unique to USP2 - compared to other family members 
(Figure 4.1).  Here, we have identified USP2-45 as a bona fide peroxisomal 
protein in primary hepatocytes (Figure 4.2).  We further go on to show that the 
C-terminal PTS1 found in UPS2-45 is critical for its localization to the peroxisome.  
When the PTS1 motif was disrupted either by point mutation or complete deletion 
we found USP2-45 localized in the cytoplasm (Figure 4.3).  From these 
experiments it does not seem as though USP2-45 PTS1 mutants affect 
peroxisome morphology or abundance but detailed experiments analyzing these 
parameters have not been completed.  At this point it is still unclear what role 
UPS2-45 might be playing in peroxisome function.   
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 One possible function of USP2-45 is changing the ubiquitin state of PEX5, 
one of the soluble receptors responsible for PTS1 mediated import.  As briefly 
discussed above PEX5 binds to the PTS1 motif of target proteins, where by 
facilitating cargo transport to the luminal side of the peroxisome – PEX5 is then 
recycled back to the cytosol.  During the cargo unloading and recycling phase 
PEX5 is mono- or poly-ubiquitinated.  In the monoubiquitinated state PEX5 is 
cycled back to the cytosol (before which point it is deubiquitinated), or in the case 
of polyubiquination it is thought to be targeted for proteasomal degradation [8].  It 
must be noted that while evidence points to de-ubiquitination as a key step in 
recycling the PEX5 receptor back to the cytosol no candidate gene, either in 
mammals or yeast, have been identified.  It is possible that USP2-45 serves in 
this role regulating the ubiquitination state of PEX5 either saving it from 
degradation or aiding recycling to the cytosol.  At least in the experiments above 
over-expression of wild-type or mutant USP2-45 in primary hepatocytes does not 
affect peroxisome import as catalase can still be observed in the peroxisome.  In 
this case more experiments are need to interrogate this line of thinking.   
 Another possibility is USP2-45 having an affect on peroxisomal fatty acid 
oxidation.  The liver is a key organ for handling fatty acids especially during times 
of fasting.  We also know that over-expression and knock-down experiments in 
HFD mice does have an affect on serum free fatty acids (FFAs) especially in the 
fasting state (Chapter 3).  However, whether or not this phenotype involves 
USP2-45 function in peroxisomes is still unclear.  One way to answer this 
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question is to analyze what species of FFAs are affected in these animals, such 
as VLCFAs, which are known to be elevated in peroxisome disease models.   
    
4.5.  Future Directions 
While USP2-45 is shown to localize to the peroxisome in primary 
hepatocytes it is unclear whether USP2-45 also does so in other tissues.  It has 
been demonstrated that the complement of enzymes in peroxisomes can vary 
from tissue to tissue suggesting some specificity for tissue function.  One way to 
address this would be to use other cell models like C2C12 myotubes or 
fibroblasts to see if USP2-45 localization still holds true.  A similar methodology 
would be employed to the primary hepatocyte experiments.   
 Another line of experiments would focus on the possible role of USP2-45 
on PEX5 ubiquitination state.  As mentioned above ubiquitination of PEX5 is 
required for proper recycling back to the cytosol.  To address this question we 
would perform similar in vitro ubiquitination assays like the ones carried out for 
HSD1 in chapter 3.  Using co-transfection experiments with wild-type and 
catalytically dead USP2-45 we could determine whether USP2-45 can 
deubiquitinate PEX5.    
 Finally, over-expression of USP2-45 PTS1 mutants might help elucidate 
the role peroxisomes might be playing in the observed phenotype of USP2-45 in 
liver tissue.  Over expression of Ad-USP2-45 in liver tissue causes an increase in 
hepatic glucose output as well as decreasing serum free fatty acid levels in HFD 
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mice.  If USP2-45 is affecting these pathways due to its localization to the 
peroxisome (and therefore peroxisome function in general) PTS1 mutants would 
be null for this phenotype.  However, it is also possible that cytoplasmic 
localization of USP2-45 (as observed in primary hepatocytes) might cause a 
plethora of other off target effects confounding the phenotype.    
 
4.6.  Materials and Methods 
Immunofluorescence confocal microscopy.  Primary hepatocytes were 
harvested and cultured as previously described (Chapter 2).  However, one 
notably change was 1o hepatocytes were seed in wells containing collagen 
coated cover-slips (ethanol and UV sterilized).  In Figure 4.2 primary hepatocytes 
were infected with Ad-USP2-45, fixed and stained with anti-flag and either anti-
catalase, mitotracker, or anti-lamp2.  For antibody staining, Alexafluor 
(Invitrogen) secondary antibodies were employed for fluorescent visualization.  
For Figure 4.3 cells were transfected with wild-type or mutant USP2-45 using 
polyethyleneimine (PEI, Polysciences, Inc).  Staining was similar to as described 
above.   
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Chapter 5 
 
 
Interpretation 
 
 
5.1 Circadian and metabolic regulation of USP2-45 
 In the preceding chapters we have started to unravel the mechanisms 
behind the regulation of USP2.  These mechanisms include both circadian and 
nutritional inputs.  The regulation of USP2 is unique for the USP2-45 isoform, as 
mRNA levels of USP2-69 remain similar under these conditions.  So far we have 
identified several transcription factors important for induction and suppression of 
USP2-45 expression.  In gain-of-function studies we identified both PGC-1α and 
PGC-1β as potent activator of UPS2-45 transcription.  Previous studies have 
demonstrated that PGC-1α coordinates several aspects of hepatic fasting 
response, including the activation of gluconeogenesis, heme biosynthesis, and 
fatty acid β-oxidation [1-3].  However, whether PGC-1α or PGC-1β is required for 
USP2-45 regulation in a fasting or circadian manner has yet to be thoroughly
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explored.  This regulation of USP2-45 by the PGC-1 family co-activators seems 
to be mediated in part by at least two nuclear receptors, HNF-4α and ERRγ.  We 
also identified E4BP4, an insulin regulated transcription factor, as a potent 
negative regulator of USP2-45 expression.  Since we have demonstrated insulin 
plays a repressive role in USP2-45 regulation this might be mediated thorough 
E4BP4.  We have now identified two potential regulatory arms of USP2-45 
potentially integrating both circadian and nutritional signals.  However, 
understanding where all the transcriptions factors fit in still remains unclear.     
 
5.2 Hepatic glucose regulation through ubiquitin-specific protease 2  
Hepatic gluconeogenesis is stimulated in response to starvation and is 
critical for maintaining a steady supply of glucose for tissues that rely on glucose 
for energy production. Glucocorticoids and glucagon are major counter regulatory 
hormones that drive gluconeogenic gene expression and hepatic glucose 
production.  In mammals, diurnal feeding cycles also provide physiological cues 
that modulate hepatic gluconeogenesis.  In fact, the expression of PEPCK and 
G6Pase is highly rhythmic in rodent livers.  The mechanisms that integrate these 
hormonal and circadian signals in the regulation of gluconeogenesis are poorly 
understood.  Here in, we have characterized USP2’s role in liver glucose 
homeostasis through augmentation of glucocorticoid signaling. 
Gain- and loss- of function studies demonstrate that USP2 is required for 
proper glucose handling in liver tissue.  Adenoviral delivery of USP2-45 resulted 
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in both increased blood glucose and liver glycogen storage.  In pyruvate 
tolerance tests (PTT) mice transduced with USP2-45 showed increased glucose 
output suggesting increased gluconeogenesis.  qPCR analysis confirmed over-
expression of USP2-45 drive increases in gluconeogenic genes PEPCK and 
G6Pase.  Moreover, overexpression of USP-45 in HFD mice results in glucose 
intolerance and insulin resistance.  In this case, hepatic USP2-45 overexpression 
impairs the ability of transduced mice to clear glucose from circulation during 
GTT.  While it is possible that impaired response to insulin is local in nature, i.e. 
suppression of gluconeogenesis in the liver, we cannot rule out the possibility 
that other tissues, such as skeletal muscle and white adipose tissue, may also 
develop insulin resistance secondary to hepatic insulin resistance.  Employing a 
hyperinsulinemic euglycemic clamp would help answer this question.  In contrast, 
siUSP2 transduced mice exhibit suppressed gluconeogenesis and glycogen 
storage resulting in fasting hypoglycemia.  Interestingly, USP2 deficiency also 
results in disruption of normal diurnal glucose rhythms under restricted feeding 
conditions.  We believe that this increased glucose output is a result of increased 
hepatic glucocorticoid signaling.  In livers of USP2-45 transduced mice we 
observed an increase in glucocorticoid target genes including, IGFBP1, 
TSC22D3 and ANGPTL4.  Consistent with this we observed increased levels of 
HSD1, the enzyme responsible for glucocorticoid ligand activation, at both the 
mRNA and protein level.  In contrast, USP2 deficiency resulted in decrease 
hepatic glucocorticoid signaling and decreased protein and mRNA expression of 
HSD1.  To demonstrate that HSD1 is downstream of USP2-45 we employed a 
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chemical inhibitor for HSD1, termed CBX.  Over-expression of USP2-45 in mice 
treated with CBX resulted in decreased blood glucose levels as well as decrease 
gluconeogenic gene expression.  However, whether hepatic over-expression of 
HSD1 rescues siUSP2 mediate hypoglycemia remains to be explored.  
While the exact substrates that mediate the effects of USP2 on HSD1 
expression remain unknown at present, it is likely that certain transcription factors 
and/or cofactors that control HSD1 gene expression may be targeted by USP2-
45 in the liver. A potential candidate is C/EBPα, which has been demonstrated to 
stimulate HSD1 promoter activity [4]. In this case, deubiquitination of C/EBPα 
and/or other transcriptional regulators by USP2 may result in increased protein 
stability, leading to the induction of HSD1 expression.  
In summary we have identified an ubiquitin-specific protease, USP2-45, 
that is highly regulated by both nutritional and circadian signals (Figure 5-1).  In 
addition we have characterized USP2’s role in hepatic glucose homeostasis 
through augmentation of the glucocorticoid pathway.  However, what role USP2-
45 plays in other GR responsive tissues remains to be elucidated.  USP2-45 is 
highly expressed in other tissue and at least in muscle tissue maintains its 
circadian rhythm.  So it is plausible that USP2-45 is playing a similar role in other 
tissues.  What affect this has on glucose homeostasis or other metabolic 
parameters, has yet to be explored. 
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Figure 5-1.  USP2-45’s role in regulating glucose homeostasis through 
glucocorticoid activation.  The USP2-45 gene product is regulated by both 
clock and nutritional signals in liver tissue.  Our studies have demonstrated a role 
for USP2-45 in regulating blood glucose levels through control of liver glucose 
production and output.  This increase in glucose production is brought about by 
USP2-45’s ability to regulate HSD1 mRNA and protein levels, thereby modulating 
glucocorticoid activation.    
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